新規抗精神病薬のすべて

出版社： 先端医学社
著者：
発行日： 2004-02-01
分野： 臨床医学：一般  >  薬物療法
ISBN： 4884071255
電子書籍版： 2004-02-01 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

5,170 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

2,585 円(税込)

購入する

商品紹介

新規の薬物の作用機序が詳細に解明されることは、いまだに未知、難攻不落な統合失調症の病院に迫るものであり、今後のますますの発展が期待される。本書はその基礎的研究から、臨床での適切合理的な用い方まで、新規（非定型）抗精神病薬のすべてを網羅している。

目次

  • 新規抗精神病薬のすべて

    ―目次―

    Part1　臨床薬理編
    　1　新規抗精神病薬の薬理学的プロフィール
    　2　新規抗精神薬の薬物動態と反応性
    Part2　治療編
    　1　定型抗精神病薬と新規抗精神病薬の使い分け
    　2　海外における新規抗精神病薬の臨床評価と位置づけ
    　3　急性期における新規抗精神病薬の臨床評価
    　4　新規抗精神病薬の長期効果をめぐって
    　5　新規抗精神病薬と統合失調症の再発予防効果について
    　6　治療抵抗性統合失調症における新規抗精神病薬の有効性
    　7　欧米の治療ガイドラインにおける新規抗精神病薬の位置づけ
    　8　日本の統合失調症治療における新規抗精神病薬の位置づけ
    Part3　新規抗精神病薬を用いた臨床例
    Part4　治療上の注意点
    　1　新規抗精神病薬の単剤治療による臨床評価
    　2　統合失調症の多剤併用・大量療法
    　3　精神運動興奮が激しい場合の新規抗精神病薬による治療原則
    Part5　安全性とＱＯＬ
    　1　新規抗精神病薬とＱＯＬ
    　2　新規抗精神病薬と服薬コンプライアンス
    　3　新規抗精神病薬の副作用
    　4　新規抗精神病薬の相互作用
    　5　新規抗精神病薬の代謝系副作用
    Part6　将来展望
    　1　新規抗精神病薬が精神科領域で果たす今後の役割
    　2　デイケア通用者の体力および社会生活技能訓練
    　3　地域精神保健システムにおける新規抗精神病薬の役割
    　4　医療経済学から見た新規抗精神病薬の可能性
    　5　認知機能における新規抗精神病薬の今後の可能性
    Part7　基礎編
    　1　5-HT受容体遺伝子と統合失調症
    　2　ドパミン受容体遺伝子と統合失調症
    　3　最初期遺伝子と核内情報伝達系
    　4　統合失調症関連遺伝子
    　5　統合失調症の画像所見と画像研究

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

PART 1 臨床薬理編

P.20 掲載の参考文献
1) 久住一郎, 高橋義人, 小山司:非定型抗精神病薬の奏効機転. 神経進歩 44:958-963, 2000
 
2) Kapur S, Remington G: Dopamine D2 receptors and their role in atypical antipsychotic action: Still necessary and may even be sufficient. Biol Psychiatry 50:873-883, 2001
PubMed
3) Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry 47:27-38, 2002
PubMed
4) Garris PA, Wightman RM: Different kinetics govern dopaminergic transmission in the amygdala, prefrontal cortex and striatum, an in vivo voltammetry study. J Neurosci 14:442-450, 1994
 
5) Strange PG: Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol Rev 53:119-133, 2001
PubMed
6) Koepp MJ, Gunn RN, Lawrence AD et al: Evidence for striatal dopamine release during a video game. Nature 393:266-268, 1998
PubMed
7) Laruelle M, Abi-Dargham A, Gil R et al: Increased dopamine transmission in schizophrenia: Relationship to illness phases. Biol Psychiatry 46:56-72, 1999
PubMed
8) Seeman P, Tallerico T: Rapid release of antipsychotic drugs from dopamine D2 receptors: An explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am J Psychiatry 156:876-884, 1999
PubMed
9) Farde L, Wiesel FA, Nordstroem A-L et al: D1 and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacolgy 99:S28-S31, 1989
 
10) Kapur S, Zipursky R, Jones C et al: A positron emission tomography study of quetiapine in schizophrenia-A preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 57:553-559, 2000
 
11) Meltzer HY, Lee MA, Ranjan R et al: Relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadine. Psychopharmacology 124:176-187, 1996
PubMed
12) Csernansky JG, Mahmoud R, Brenner R: A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Eng J Med 346:16-22, 2002
 
13) Ishikane T, Kusumi I, Matsubara R et al: Effects of serotonergic agents on the up-regulation of dopamine D2 receptors induced by haloperidol in rat striatum. Eur J Pharmacol 321:163-169, 1997
PubMed
14) Seeman P, Kapur S: Schizophrenia: More dopamine, more D2 receptors. Proc Natl Acad Sci USA 97:7673-7675, 2000
PubMed
15) Abi-Dargham A, Rodenhiser J, Printz D et al: Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 97:8104-8109, 2000
PubMed
16) Kusumi I, Takahashi Y, Suzuki K et al: Differential effects of subchronic treatments with atypical antipsychotic drugs on dopamine D2 and serotonin 5-HT2A receptors in the rat brain. J Neural Transm 107:295-302, 2000
 
17) Kapur S: A new framework for investigating antipsychotic action in humans: Lessons from PET imaging. Mol Psychiatry 3:135-140, 1998
PubMed
18) Meltzer HY, Matsubara S, Lee J-C: Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J pharmacol Exp Ther 251 238-245, 1989
PubMed
19) Pietzcker A, Gaebel W, Kopcke W et al: Intermittent versus maintenance neuroleptic long-term treatment in schizophrenia:2 year results of a German multicenter study. J Psychiatr Res 27:321-339, 1993
 
20) Burris K, Molski TF, Xu C et al: Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302:381-389, 2002
PubMed
P.28 掲載の参考文献
1) Carlsson A, Lindquist M: Effect of chlorpromazine and haloperidol on formulation of 3-methoxytyramine and nometanephrine in mouse brain. Acta Pharmacol Toxicol 20:140-144, 1963
 
2) Seeman P: Brain dopamine receptors. Pharmachol Rev 32:229-313, 1980
PubMed
3) Peroutuka SJ, Snyder SH: Relationship of neuroleptic drug effects at brain dopamine, serotonin, α-adrenergic, and histamin receptors to clinical potency. Am J Psychiat 137:518-1552, 1980
 
4) Costall B, Fortune DH, Naylor RJ: Serotonergic involvement with neuroleptic catalepsy. Neuropharmacolgy 14:859-868, 1975
 
5) Lieberman JA, Mailman RB, Duncan G et al: Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol Psuchiat 44:1099-1117, 1998
PubMed
6) Janssen PAJ: The development of new antipsychotic drugs: Towards a new strategy in the management Of Chronic psychoses. Jr Drug Ther Res 12:324-328, 1987
 
7) Kane J, Honingfeid G, Singer J et al: Clozapine for the treatment-resistant schizophrenia. Arch Gen Psychiat 45:789-796, 1988
 
8) Meltzer HY, Matsubara S, Lee J-C: Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and serotonin 2 pKi values. J Pharmacol EXp Ther 251 :238-246, 1989
PubMed
9) Matsubara S, Matsubara R, Kusumi I et al: Dopamine D1, D2 and serotonin 2 receptor occupancy by typical and atypical antipsychotic drugs in vivo J Pharmacol Exp Ther 265:498-508, 1993
PubMed
10) Stockmeier CA, DiCarlo JJ, Thompson P et al: Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin 2 and dopamine 2 receptors. J Pharmacol Exp Ther 266:1374-1384, 1993
 
11) Nordstroem A-L, Farde L, Halldin C: High 5-HT2 receptor occupancy in clozapine treated patients demonstrated by PET. Psychopharmachol 110:365-367, 1993
 
12) Meltzer HY: The role of serotonin in antipsychotic drug action. Neuropsychopharmachol 21:106S-115S, 1999
PubMed
P.34 掲載の参考文献
1) Bantick RA, Deakin JFW, Grasby PM: The 5-HTIA receptor in schizophrenia: a promising target for novel atypical neuroleptics? J Psychopharmacology 15:37-46, 2001
 
2) Millan MJ: Improving the treatment of schizophrenia: focus on serotonin (5-HT)1A receptors. J Pharmacol Exp Ther:295:853 861, 2000
 
3) Bames NM, Sharp T: A review of central 5-HT receptors and their function. Neuropharmacology 38:1083-1152, 1999
 
4) Hashimoto T, Nishino N, Nakai H et al: Increase in serotonin 5-HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. Life Sci 48:355-363, 1991
PubMed
5) Joyce JN, Shane A, Lexow N et al: Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology 8:315-336, 1993
PubMed
6) Sumiyoshi , T Stockmeier CA, Overholser JC et al: Serotonin1A receptors are increased in postmertem prefrontal cortex in schizophrenia. Brain Res 708:209-214, 1996
PubMed
7) Simpson MDC, Lubman DI, Slater P et al: Autoradiography with [3H]8-OH-DPAT reveals increases in 5-HT1A receptors in ventral prefrontal cortex in schizophrenia. Biol Psychiatry 39:919-928, 1996
 
8) Bumet PWJ, Eastwood SL, Harrison PJ:5-HT1A and 5-HT2A receptor mRNAs and binding sites are differentially altered in schizophrenia. Neuropsychopharmacology 15:442-455, 1996
 
9) Burnet PWJ, Eastwood SL, Harrison PJ:[3H] WAY-100635 for 5-HT1A receptor autoradiography in human brain: a comparison with[3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia. Neurochem Int 30:565-574, 1997
 
10) Gurevich EV, Joyce JN: Alterations in the cortical serotonergic system in schizophrenia: a postmortem study. Biol Psychiatry 42:529-545, 1997
PubMed
11) Slater P, Doyle CA, Deakin JFW: Abnormal persistence of cerebellar serotonin-1A receptors in schizophrenia suggests failure to regress in neonates. J Neural Transm 1105:305-315, 1998
 
12) Dean B, Tomaskovic-Crook E, Opeskin K et al: No change in the density of the serotonin1A receptor, the serotonin4 receptor or the serotonin transporter in the dorsolateral prefrontal cortex from subjects with schizophrenia. Neurochem Int 34:109-115, 1999
PubMed
13) Tauscher J, Kapur S, Verhoeff PLG et al: Brain serotonin 5-HTIA receptor binding in schizophrenia measured by positron emission tomography and [11C] WAY-100635. Arch Gen Psychiatry 59:514-520, 2002
 
14) Newman-Tancredi A, Chaput C, Verriele L et al: Clozapine is a partial agonist at cloned, human serotonin 5-HTIA receptors. Neuropharmacology 35:119-121, 1996
 
15) Rollema H, Lu Y, Schmidt AW et al: Clozapine increases dopamine release in prefrontal cortex by 5-HTIA receptor activation. Eur J Pharmacology 338: R3-R5, 1997
 
16) Rollema H, Lu Y, Schmidt AW et al:5-HT1A receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatry 48:229-237, 2000
 
17) Seeger TF, Seymour PA, Schmidt AW et at: Ziprasidone (CP-88, 059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 275:101-113, 1995
PubMed
18) Assie M-B, Cosi C, Koek W: 5-HT1A receptor agonist properties of the antipsychotic, nemonapride: comparison with bromeguride and clozapine. Eur J Pharmacology 334:141-147, 1997
PubMed
19) Newman-Tancredi A, Gavaudan S, Conte C et al: Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a[35S]GTPySbinding study. Eur J Pharmacology 355:245-256, 1998
PubMed
20) Elliott J, Reynolds GP: Agonist-stimulated GTPy[35S]binding to 5-HT1A receptors in human post-mortem brain. Eur J Pharmacology 386:313-315, 1999
 
21) Cosi C, Koek W: The putative<silent>5-HT1A receptor antagonist, WAY 100635, has inverse agonist properties at cloned human 5-HT1A receptors. Eur J Pharmacology 401 :9-15, 2000
 
22) Cosi C, Koek W: Agonist, antagonist, and inverse agonist properties of antipsychotics at human recombinant 5-HT1A receptors expressed in HeLa cells. Eur J Pharmacology 433:55-62, 2001
 
23) Schmidt AW, Lebel LA, Howard HR Jr et al: Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacology 425:197-201, 2001
PubMed
24) Newman-Tancredi A, Verriele L, Millan MJ: Differential modulation by GTPyS of agonist and inverse agonist binding to h5-HT1A receptors revealed by[3H]WAY . Brit J Pharmacology 132:518-524, 2001
 
25) Newman-Tancredi A, Verriele L, Touzard M et al: Efficacy of antipsychotic agents at human 5-HTIA receptors determined by[3H]WAY 100,635 binding affinity ratios: relationship to efficacy for G-protein activation. Eur J Pharmacology 428:177-184, 2001
 
26) Jordan S, Koprivica V, Chen R et al: The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacology 441:137-140, 2002
PubMed
27) Sovner R, Pamell-Sover N: Use of buspirone in the treatment of schizophrenia. J Clin Psychopharmacology 9 61-62, 1989
 
28) D'Mello DA, McNeil JA, Harris W: Buspirone suppression of neuroleptic-induced akathisia: multiple case reports. J Clin Psychopharmacology 9:151-152, 1989
 
29) Brody D, Adler LA, Kim T et al: Effects of buspirone in seven schizophrenic subjects. J Clin Psychopharmacology 10:68-69, 1990
 
30) Goff DC, Midha KK, Brotman AW et al: An open trial of buspirone added to neuroleptics in schizophrenic patients. J Clin Psychopharmacology 11:193-197, 1991
 
31) Pantelis C, Bames TRE: Acute exacerbation of psychosis with buspirone? J Psychopharmacology 7:295-300, 1993
 
32) Decina P, Mukherjee S, Bocola V et al: Adjunctive trazodone in the treatment of negative symptoms of schizophrenia. Hosp Commun Psychiatry: y 45:1220 1223, 1994
 
33) Sumiyoshi T, Matsui M, Yamashita I et al: Effect of adjunctive treatment with serotonin-1A agonist tandospirone on memory functions in schizophrenia. J Clin Psychopharmacologyy 20 386-388, 2000
 
34) Sumiyoshi T, Matsui M, Yamashita I et al: The effect of tandospirone, a serotonin1A agonist, on memory function in schizophrenia. Biol Psychiatry 49:861-868, 2001
PubMed
35) Sumiyoshi T, Matsui M, Nohara S et al: Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry 158:1722-1725, 2001
PubMed
36) Sirota P, Epstein B, Benatov R et al: An open study of buspirone augmentation of neuroleptics in patients with schizophrenia. J Clin Psyhopharmacology 21:454-455, 2001
 
37) Berk M, Ichim C, Brook S: Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a doubleblind randomized placebo-controlled study. Int Clin Psychopharmacology 16:87-92, 2001
 
38) Caspi N, Modai I, Barak P et al: Pindolol augmentation in aggressive schizophrenic patients: a double-blind crossover randomized study. Int Clin Psychopharmacology 16:111-115, 2001
 
39) Gobert A, Rivet J-M, Audinot V et al: Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto-and heteroreceptor-mediated control of release. Neuroscience 84:413-429, 1998
PubMed
40) Friedma JI, Temporini H, Davis KL: Pharmacologic strategies for augmenting cognitive performance in schizophrenia. Biol Psychiatry 45:1-16, 1999
 
P.43 掲載の参考文献
1) Fang J, Bourin M, Baker GB: Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol 359:147-151, 1999
PubMed
2) Lavrijsen KL, Heykants JJ: Narcotic analgesics and debrisoquine polymorphism. Anesthesiology 71:474-475, 1989
PubMed
3) Mannens G, Huang ML, Meuldermans W et al: Absorption, metabolism, and excretion of risperidone in humans. Drug Metab Dispos 21:1134-1141. 1993
PubMed
4) Olesen OV, Licht RW, Thomsen E et al: Serum concentrations and side effects in psychiatric patients during risperidone therapy. Ther Drug Monit 20:380-384, 1998
PubMed
5) Scordo MG, Spina E, Facciola G et al: Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl) 147:300-305, 1999
PubMed
6) Bork JA, Rogers T, Wedlund PJ et al: A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. J Clin Psychiatry 60:469-476, 1999
 
7) Huang ML, Van Peer A, Woestenborghs R et al: Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 54:257-268, 1993
PubMed
8) Johansson I, Oscarson M, Yue Q et al: Genetic analysis of the Chinese cytochrome P4502D locus: Characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 46:452 459, 1994
 
9) Bertilsson L, Dahl ML: Polymorphic drug oxidation. Relevance to the treatment of psychiatric disorders. CNS Drugs 5:200-223, 1996
 
10) Roh HK, Kim CE, Chung WG et al: Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients. Eur J Clin Pharmacol 57:671-675, 2001
PubMed
11) Spina E, Scordo MG, Avenoso A et al: Adverse drug interaction between risperidone and carbamazepine in a patient with chronic schizophrenia and deficient CYP2D6 activity. J Clin Psychopharmacol 21:108-109, 2001
 
12) Spina E, Avenoso A, Facciola G et al: Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine. Ther Drug Monit 23:223-227, 2001
PubMed
13) Yasui-Furukori N, Hidestrand M, Spina E et al: Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos 29:1263-1268, 2001
PubMed
14) Chong SA, Remington G: Clozapine Augmentation: Safety and Efficacy. Schizophr Bull 26:421-440, 2000
PubMed
15) Perry PJ, Miller DD, Arndt SV et al: Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 148:231-235, 1991
PubMed
16) Kronig MH, Munne RA, Szymanski S et al: Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am J Psychiatry 152:179-182, 1995
PubMed
17) Hasegawa M, Gutierrez-Esteinou R, Way L et al: Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. J Clin Psychopharmacol 13:383-390, 1993
PubMed
18) VanderZwaag C, McGee M, McEvoy JP et al: Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am J Psychiatry 153:1579-1584, 1996
PubMed
19) Narendran R, Young CM, Pristach CA et al: Efficacy of clozapine in the treatment of atypical antipsychotic refractory schizophrenia: a pilot study. J Clin Psychopharmacol 23:103-104, 2003
PubMed
20) Henning U, Loffler S, Krieger K et al: Uptake of clozapine into HL-60 promyelocyclic leukaemia cells. Pharmacopsychiatry 35:90-95, 2002
PubMed
21) Freeman DJ, Oyewumi LK: Will routine therapeutic drug monitoring have a place in clozapine therapy? Clin Pharmacokinet 32:93-100, 1997
PubMed
22) Detting M, Sachse C, Muller-Oerlinghausen B et al : Clozapine-induced agranulocytosis and hereditary polymorphisms of clozapine metabolizing enzymes. Pharmacopsychiatry 33:218-220, 2000
 
23) Bredbacka PE, Paukkala E, Koponen H: Can severe cardiorespiratory dysregulation induced by clozapine monotherapy be predicted? Int Clin Psychoparmacol 8:205-206, 1993
PubMed
24) Chong SA, Tan CH, Lee HS: Hoading and clozapine-risperidone combination. (letter) J Clin Psychiatry 41:315-316, 1996
 
25) Honigfeld G: The clozapine National Registry system: forty years of risk management. J Clin Psychiary 14:29-32, 1996
 
26) Honigfeld G, Arellano F, Sethi J et al: Reducting clozapine-related morbidity and mortality:5 years of experience with the Clozapine National Registry. J Clin Psychiatry 59:3-7, 1998
 
27) Callaghan JT, Bergstrom RE Ptak LR et al: Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 37:177-193, 1999
 
28) Ring BJ, Catlow J, Lindsay TJ et al: Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther 276:658-666, 1996
PubMed
29) Hiemke C, Peled A, Jabarin M et al: Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects. J Clin Psychopharmacol 22:502-506, 2002
PubMed
30) Rao ML, Hiemke C, Grasmader K et al: TDM Arbeitsgruppe Der AGNP. Olanzapine: pharmacology, pharmacokinetics and therapeutic drug monitoring Fortschr Neurol Psychiatr 69:510-517, 2001
PubMed
31) Markowitz JS, DeVane CL: Suspected ciprofloxacin inhibition of olanzapine resulting in increased plasma concentration. Clin psychopharmacol 19:289-291, 1999
 
32) Lucas RA, Gilfillan DJ, Bergstrom RF: A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism. Eur J Clin Pharmacol 54:639-643, 1998
PubMed
33) Perry PJ, Lund BC, Sanger T et al: Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial. J Clin Psychopharmacol 21:14-20, 2001
 
34) Ellingrod VL, Perry PJ, Lund BC et al:5HT2A and 5HT2c receptor polymorphisms and predicting clinical response to olanzapine in schizophrenia. J Clin Psychopharmacol 22:622-624, 2002
PubMed
35) Skogh E, Reis M, Dahl ML et al: Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting. Ther Drug Monit 24:518-526, 2002
PubMed
36) Prior TI, Chue PS, Tibbo P et al: Drug metabolism and atypical antipsychotics. Eur Neuropsychopharmacol 9:301-309, 1999
PubMed
37) Savasi I, Millson RC, Owen JA: Quetiapine blood level variability. Can J Psychiatry 47:94, 2002
PubMed
38) DeVane CL, Nemeroff CB: Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet 40:509-522, 2001
PubMed
39) 藤本恵一, 水野佳子, 金丸博也: SM-9018の代謝物の検索と同定. 基礎と臨床 31:581-657, 1997
 
40) 石橋正, 大野行弘, 徳田久美子ほか: 塩酸perospirone主要代謝産物の中枢薬理作用. 基礎と臨床 31:893-902, 1997
 
41) 広兼元太, 染矢俊幸, 柴崎守和ほか: プロムペリドール代謝の個体差と臨床症状改善度との関連. 神経精神薬理 19:39-49, 1997
 
42) Someya T, Takahashi S, Shibasaki M et al: Reduced haloperidol/haloperidol ratios in plasma: polymorphism in Japanese psychiatric patients. Psychiatry Res 31 :111-120, 1990
PubMed
43) Magliozzi JR, Hollister LE, Amold KV et at: Relationship of serum haloperidol levels to clinical response in schizophrenic patients. Am J Psychiatry 138:365-367, 1981
 
44) Van Putten T, Marder SR, Wirshing WC et al: Neuroleptic plasma levels. Schizophr Bull 17:197-216, 1991
PubMed
45) 高木哲郎, 渡辺健一郎, 猪山茂ほか: 精神分裂病に対するbromperidolの治療効果と血中濃度. 臨床と研究 66:294-300, 1986
 
46) 染矢俊幸, 広兼元太, 高橋三郎ほか: ハロペリドール代謝の個体差と臨床症状改善度との関連. 神経精神薬理 18:511-519, 1996
 
47) 染矢俊幸, 鈴木雄太郎: 【分裂病の治療ガイドライン】分裂病の薬物療法, 薬物療法アルゴリズムと治療の実際, 抗精神病薬治療におけるTDMの有用性と問題点. 精神科治療学15 (増刊):169-174, 2000
 

PART 2 治療編

P.52 掲載の参考文献
1) 風祭元: 日本における抗精神病薬の導入と開発の歴史. Schizophrenia Frontier 2:75-80, 2001
Medical*Online
2) Leucht S, Pitschel-Walz, Abraham D et al: Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 35:51-68, 1999
PubMed
3) Geddes J, Freemantle N, Harison P et al: A typical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis. Br Med J 321:1371-1376, 2000
 
4) Waraich PS, Adams CE, Roque M et at: Haloperidol dose for the acute phase of schizophrenia (Cochrane Review). In: The Cochrane Library, Issue 1, 2003. Oxford: Update Software.
 
5) Kennedy E, Song F, Hunter R et al: Risperidone versus typical antipsychotic medication for schizophrenia (Cochrane Review). In: The Cochrane Library, Issue 1, 2003. Oxford: Update Software.
 
6) De Haan L, Van Bruggen M, Lavalaye J et al: Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. Am J Psychiatry 160:303-309, 2003
PubMed
7) Leucht S, Bames TR, Kissling W, et al: Relapse prevention, in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 160:1209-22, 2003
 
8) Davis JM, Chen N, Glick ID: Ameta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60:553-64, 2003
 
9) Guidance on the use of newer (atypical) antipsy chotic drugs for the treatment of schizophrenia. Technology Appraisal Guidance-No. 43 National Institute for Clinical Excellence, London, 2002
 
10) Osser DN: Consultant for the Pharmacotherapy of Schizophrenia. Version 2. 8, 2002. http://www.mhc.com/Algorithms/Schizophrenia/qframe.htm
 
11) Opler LA, Feinberg SS: The role of pimozide in clinical psychiatry: a review. J Clin Psychiatry 52:221-233, 1991
PubMed
12) Tohen M, Zhang F, Taylor CC et al: A meta-analysis of the use of typical antipsychotic agents in bipolar disorder J Affect Disord 65:85-93, 2001
PubMed
13) Yatham LN: Mood stabilization and the role of antipsychotics. Int Clin Psychopharmacol 17 (Suppl 3):S21-27, 2002
 
14) Newcomer JW, Haupt DW, Fucetola R et al: Abnormalities in glucose regulation during antipsychotis treatment of schizophrenia. Arch Gen Psychiatry 59:337-345, 2002
PubMed
15) Allison DB, Mentore JL, Heo M et al: Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156:1686-1696, 1999
PubMed
16) Binder RL, McNiel DE: Contemporary practices in managing acutely violent patients in 20 psychiatric emergency rooms. Psychiatry Services 50:1553-1554, 1999
PubMed
17) Battaglia J, Moss S, Rush J: Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emergency Medicine 15:335-340, 1997
PubMed
18) Garza-Trevino E, Hollister L, Overall J et al: Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. Am J Psychiatry 146:1598-1601, 1989
PubMed
19) Ward RK, Zamorski MA: Benefits and risks of psychiatric medications during pregnancy. Am Fam Physician 66:629-636, 2002
PubMed
20) Viguera AC, Cohen LS, Baldessarini RJ et al: Managing bipolar disorder during pregnancy: weighing the risks and benefits. Can J Psychiatry 47:426-436, 2002
PubMed
21) 佐藤孝道, 加野弘道編: 実践妊娠と薬-1, 173 例の相談事例とその情報-. 薬業時報社, 東京, 1992, pp. 173-183
 
22) Cohen LS, Rosenbaum JF: Psychotropic drug use during pregnancy: weighing the risks. J Clin Psychiatry 59 (Suppl 2):18-28, 1998
 
23) Goldstein DJ, Corbin LA, Fung MC: Olanzapine exposed pregnancies and lactation: early experience. J Clin Psychopharmacol 20:399-403, 2000
PubMed
24) Ernst CL, Goldberg JF: The reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics. J Clin Psychiatry 63 (Suppl 4):42-55, 2002
 
P.60 掲載の参考文献
1) Kane JM, Honigfeld G, Singer J et al: Clozapine for the treatment-resistant schizophrenia. Arch Gen Psych 45:789-796, 1988
 
2) Meyer PS, Bond GR, Tunis SL et al: Comparison between the effects of atypical and traditional antipsychotic rehabilitation program. J Clin Psychiatry 63:108-116, 2002
PubMed
3) Schooler N, Kane J, Marder S et al: Efficacy of clozapine vs haloperidol in a long-terrn clinical trial: preliminary findings. Presented at annual meeting of American College of Neuropsychopharmacology, San Juan, Puerto Rico, 1994
 
4) Atkin K, Kendall F, Gould D et al: Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psych 169:483-488, 1996
 
5) Mallya AR, Roos PD, Roebuck-Colgan K: Restraint, seclusion and olanzapine. J Clin Psychiatry 53:395-397, 1992
 
6) Meltzer HY, Alphs L, Green AI et al: Clozapine treatment for suicidality in schizophrenia. Arch Gen Psych 60:82-91, 2003
 
7) Chouinard G, Jones B, Remington G et al: A Canadian multi center placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenia patients. J Clin Psychopharmacol 13:25-40, 1993
 
8) Marder SR, Meibach RC: Risperidone in the treatment of schizophrenia. Am J Psychiatry 151:825-835, 1994
PubMed
9) Nyeberg S, Eriksson B, Oxenstierna G et al: Suggested minimal effective dose of risperidone on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Am J Psych 156:869-875, 1999
 
10) Umbricht D, Kane JM: Risperidone: efficacy and safety. Schizophrenia Bull 21:593-606, 1995
PubMed
11) Emsley RA: Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Schizophr Bull 25:721-729, 1999
PubMed
12) Csernansky JG, Mahmoud RM, Brenner R: A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. New Eng J Med 346:16-22, 2002
 
13) Marder SR, Shirley M, Wirshing WC et al: Maintenance treatment of schizophrenia with risperidone or haloperidol:2-year outcomes, Am J Psychiatry 160:1405-1412, 2003
PubMed
14) Beasley CM, Tollefson G, Tran P et al: Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14:111-123, 1996
PubMed
15) Tollefson GD, Beasley CM, Tran P: Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 154:457-465, 1997
PubMed
16) Tollefson GD, Sanger TM, Lu Y et al: Depressive signs and symptoms in schizophrenia: A prospective blinded trial of olanzapine and haloperidol Arch Gen Psych 55:250-258, 1998
 
17) Martin J, Gomez JC, Garcia-Bemardo E et al: Olanzapine and treatment-refractory schizophrenia: results of an open-label study. J Clin Psychiatry 58:479-491, 1997
 
18) Baldaccino AM, Stubbs JH, Nevson-Andrews D: The use of olanzapine in non-compliant or treatment-resistant clozapine populations in hospital Pharmacol 260:207-209, 1998
 
19) Brier A, Hamilton SH: Comparative efficacy of olanzapine and haloperidol for patients with treat resistant schizophrenia. Biolog Psych 45:403-410, 1999
 
20) Conley RR, Tamminga CA, Bartko JJ et al: Olanzapine compared with chlorpromazine in treatment resistant schizophrenia. Am J Psychiatry 155:914-920, 1998
PubMed
21) Lieberman J, Charles HC, Sharma T et al: Antipsychotic treatment effects on progression of brain pathomorphology in first episode schizophrenia. Poster presented at ninth International Congress on Schizophrenia Research, Colorado Springs, USA, 2003
 
22) Lieberman JA, Tollefson G, Tohen M et al: Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 160:1396-1404, 2003
PubMed
23) Caro JJ, Ward CM, Levinton C et al: The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry 63:1135-1139, 2002
 
24) Small JG, Hirsch SR, Arvanitis LA et al: Quetiapine in patients with schizophrenia: high-and low-dose double blind comparison with placebo. Arch Gen Psych 54:549-557, 1997
 
25) Sharma T: Quetiapine-efficacy in different domains. Eur Neuropsychopharmacology. (Suppl 4): S385-390, 2001
 
26) Velligan DI, Newcomer J, Pultz J et al: Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophrenia Res 53:239-248, 2002
PubMed
27) Keck P JR, Bufferstein A, Ferguson J et al: Ziprasidone 40 and 120 mg/day and the acute exacerbation of schizophrenia and schizoaffective disorder: a four-week placebo-controlled trial. Psychopharmacol 140:173-184, 1998
 
28) Daniel DG, Zimbroff DL, Potkin SG et al: Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a six-week placebo-controlled trial. Neuropsychopharmacology 20:490-505, 1999
 
29) McQuade RD, Kujawa A, Saha AR et al: Aripiprazole for long-term maintenance treatment of schizophrenia. Poster presented at ninth International Congress on Schizophrenia Research, Colorado Springs, USA, 2003
 
30) Taylor D: Ziprasidone in the management of schizophrenia: the QT interval issue in context. CNS Drugs 17:423-430, 2003
 
31) Fleischhacker WW, Barnas C, Stuppack CH et al: Zotepine versus haloperidol in paranoid schizophrenia: a double-blind trial. Psychopharmacol Bull 25:97-100, 1989
 
32) Petit M, Raniwalla J, Tweed J et al: A comparisonof an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: A parallel-group double blind trial. Psychopharmacol Bull 32:81-87, 1996
 
33) Bamas C, Stuppack CH, Miller C et al: Zotepine in the treatment of schizophrenic patients with prevailingly negative symptoms. A double-blind trial vs haloperidol. Int Clin Psychopharm 7:23-27, 1992
 
34) Cooper S, Butler A, Tweed J et al: Zotepine in the recurrence: a randomized, double-blind, placebo-controlled study for chronic schizophrenia. Psychopharmacology 150:237-243, 2000
PubMed
35) Geddes J, Freemantle N, Harrison P et al: Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 321:1371-1376, 2000
PubMed
36) Davis JM, Chen N, Glick ID: A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60:553-564, 2003
PubMed
37) Leucht S, Pitschel-Walz G, Abraham D et al: Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophrenia Research 35:51-68, 1999
PubMed
38) Leucht S, Barnes T, Kissling W et al: Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 160:1209-1222, 2003
PubMed
39) Tuunainen A, Wahlbeck K, Gilbody S: Newer atypical antipsychotic medication in comparison to clozapine: asystematic review of randomized trials. Schizophrenia Res 56:1 10, 2002
 
40) Wahlbeck K, Cheine M, Essali A et al: Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psych 156:990-999, 1999
 
41) Woodward ND, Purdon SE, Zald DH: A meta-analysis of neuropsychological change with second generation treatment in schizophrenia. Poster presented at ninth International Congress on Schizophrenia Research, Colorado Springs, USA, 2003
 
P.74 掲載の参考文献
1) Conrad K: Die beginnende Schizophrenie, Georg Thieme, Stuttgart, 1958 (吉永訳: 精神分裂病, 医学書院, 東京, 1973)
 
2) Herz MI, Lamberti JS: Prodromal symptoms and early intervention in schizophrenia. Neurology, Psychiatry and Brain Research 6:37-44, 1998
 
3) Herz MI, Lamberti JS, Mintz J et al: A program of relapse prevention in schizophrenia. A controlled study. Arch Gen Psychiatry 57:277-283, 2000
 
4) Birchwood M, Smith J, MacMillan F et al: Predicting relapse in schizophrenia: the development and implementation of an early signs monitoring system using patients and families as observers, a preliminary investigation. Psychol Med 19:649-656, 1989
 
5) Stahl SM: Essential Psychopharmacology (Neuroscientific Basis and Practical Applications) Second Edition. 精神薬理学エセンシャルズ. メディカル・サイエンス・インターナショナル:2002pp. 356-445
 
6) Goldstein JM: Atypical antipsychotic drugs: beyond acute psychosis, new directions. Emerg Drugs 4:127-151, 1999
 
7) Kapur S, Remington G: Atypical Antipsychotics: New Directions and New Challenges in the Treatment of Schizophrenia. Annu Rev Med 52:503-517, 2001
PubMed
8) Emsley RA: Risperidone in the Treatment of First-Episode Psychotic Patients: A Double-Blind Multicenter Study. Schizophrenia Bulletin 25:721-729, 1999
PubMed
9) Currier GW, Simpson GM: Risperidone Liquid Concentrate and Oral Lorazepam Versus Intramuscular Haloperidol and Intramuscular Lorazepam for Treatment of Psychotic Agitation. J Clin Psychiatrly 62:153-157, 2001
 
10) Beasley CM, Jr, Hamilton SH, Crawford AM et al: Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. European Neuropsychopharmacology 7:125-137, 1997
PubMed
11) Sanger TM, Lieberman JA, Tohen M:Olanzapine Versus Haloperidol Treatment in First-Episode Psychosis.Am J Psychiatry 156:79-87, 1999
PubMed
12) Arvanitis LA, Miller BG, the Seroquel Trial 13 Study Group: Multiple Fixed Doses of "Seroquel" (Quetiapine) in Patients with Acute Exacerbation of Schizophrenia: A Comparison with Haloperidol and Placebo. Biol Psychiatry 42:233-246, 1997
 
13) Copolov DL, Link CGG, Kowalcyk B: A multicentre, double-blind, randomized comparison of quetiapine ( ICI 204, 636, 'Seroquel') and haloperidol in schizophrenia. Psychol Med 30:95-105, 2000
 
14) Petit M, Raniwalla J, Tweed J et al: A Comparison of an Atypical and Typical Antipsychotic, Zotepine Versus Haloperidol in Patients With Acute Exacerbation of Schizophrenia: A Parallel-Group Double-Blind Trial. Psychopharmacology Bulletin 32:81-87, 1996
 
15) Kasper S, Quiner S, Barnas C et al: Zotepine in the treatment of acute hospitalized schizophrenic episodes. Int Clin Psychopharmacol 16:163-168,
PubMed
16) Cooper SJ, Tweed J, Raniwalla J et al: A placebo-controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia. Acta Psychiatr Scand 101:218-225, 2000
PubMed
17) Ho BC, Miller D, Nopoulos P et al: A Comparative Effectiveness Study of Risperidone and Olanzapine in the Treatment of Schizophrenia. J Clin Psychiatry 60:658-663, 1999
PubMed
18) Briken P, Nika E, Moritz S et al: Effect of zotepine, olanzapine and risperidone on hostility in schizophrenic patients. Schizophr Res 57:311-313, 2002
PubMed
19) "The Expert Consensus Guideline Series: Treatment of Behavioral Emergencies." アルタ出版, 東京, 2001, pp. 100
 
20) Kablinger AS, Freeman III AM: Prodromal Schizophrenia and Atypical Antipsychotic Treatment. J Nerv Ment Dis 188:642-652, 2000
 
21) 堤祐一郎: 急性期精神分裂病に対する従来型抗精神病薬の問題点 (第2世代抗精神病薬risperidone との比較において), 臨床精神薬理5:1147-1154, 2002
 
22) Tsutsumi Y: Usefulness of Risperidone for Acute Schizophrenia: Study of 170 Cases. X II WPA Ybkohama, Abstracts Vol. 2:325, 2002
 
23) 堤祐一郎: 統合失調症急性期症状に対する向精神薬剤 (注射製剤含む) 使用の変遷. 第11回日本精神科救急学会抄録集, 2003, pp. 68
 
24) 堤祐一郎: 精神分裂病の急性期症状に対する望ましい薬物療法, 臨床精神薬理 5:619-627, 2002
 
25) Garza-Trevino E, Hollister L, Overall J et al: Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. Am J Psychiatry 146:1598-1601, 1989
PubMed
26) Wyant M, Diamond B, O'Neal E et al: The use of midazolam in acutely agitated psychiatric patients. Psychopharmacol Bull 26:126-129, 1990
PubMed
27) Salzman C, Solomon D, Miyawaki E et al: Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. J Clin Psychiatry 52:177-180, 1999
 
28) Salzman C, Green A, Rodriguez-Villa F et al: Benzodiazepine combined with neuroleptics for management of severe disruptive behavior. Psychosomatics 27:17-21, 1986
PubMed
29) Wright S, Chudofsky C, Dronen S et al: Midazolam use in the emergency department. Am J Emerg Med 8:97-100, 1990
 
30) Saltzman C: Use of benzodiazepines to control disruptive behavior in inpatients. J Clin Psychiatry 49:13-15, 1988
 
31) Chengappa KN: Impact of Risperidone on Seclusion and Restraint at a State Psychiatric Hospital. Can J Psychiatry 45:827-832, 2000
 
32) Butler A, Wighton A, Welch CP et al: The efficacy of zotepine in schizophrenia: A meta-analysis of BPRS and improvement scale scores. Int J Psychiatry Clin Practice 4:19-27, 2000
 
33) Schotte A, Bonaventure P, Janssen PF et al: In vitro receptor binding and in vivo receptor occupancy in rat and guinea pig brain: risperidone compared with antipsychotics hitherto used. Jpn J Pharmacol 69:399-412, 1995
PubMed
34) Schotte A, Janssen PF, Gommeren W et al: Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124 (Berl):57-73, 1996
PubMed
35) 中込和幸, 上島国利: 精神分裂病の前駆症状としての不安・抑うつ. 臨床精神薬理 5:281-287, 2002
 
P.85 掲載の参考文献
1) JG Csernansky, R Mahmoud, R Brenner: A Comparison of Risperidone and Haloperidol for the Prevention of Relapse in Patients with Schizophrenia. New England Journal of Medicine 346:16-22, 2002
 
2) KJ Aitchison, K Meehan, RM Murray: First Episode Psychosis-初回エピソード精神病, 嶋田博之ほか (訳). 星和書店, 東京, 2000, pp. 1-9
 
3) NC Andreasen: 新Bleuler学説に基づく精神分裂病の単一疾患モデル, (平安良雄ほか監訳). 臨床精神薬理 5:553-575, 2002
 
4) NC Andreasen: 精神分裂病の治療-目標は何か, (山内俊雄監訳). 臨床精神薬理 5:1318-1328, 2002
 
5) 中安信夫: 背景思考の聴覚化-幻声とその周辺症状をめぐって-. 分裂病の精神病理14. 内沼幸雄編, 東京大学出版会, 東京, 1985, pp. 199-235
 
6) 中安信夫: 背景知覚の偽統合化-妄想知覚の形成をめぐって-. 分裂病の精神病理15. 高橋俊彦編, 東京大学出版会, 東京, 1986, pp:97-231
 
7) 中安信夫: 精神病理学における「記述」とは何か. 臨床精神病理 14:15-31, 1993
 
8) 高柴哲次郎: 外来治療と入院治療を含む標準的な治療ための基本条件-慢性化防止に向けて, 基本となる臨床能力を検討する. 新世紀の精神科治療10, 慢性化防止への治療的働きかけ, 中山書店, 東京, 印刷中
 
P.93 掲載の参考文献
1) Prudo R, Bulm HM: Five-year outcome and prognosis in schizophrenia: a report from the London Field Research Center of the International Pilot Study of Schizophrenia. Br J Psychiatry 150:345-354, 1987
 
2) Kane JM: Management strategies for the treatment of schizophrenia. J Clin Psychiatry 60 (Suppl 12) :13-17, 1999
 
3) Csernansky J. Okamoto A, Brecher M: Risperidone vs haloperidol for prevention of relapse in schizophrenia and affective disorders: a long-term double-blind comparison. 54th the society of biological psychiatry, Washington DC. May 1999
 
4) 諸川由実代: 非定型抗精神病薬と定型抗精神病薬の徹底比較-長期投与試験-臨床精神薬理 5:167-176, 2002
 
5) Beasley CM Jr, Tollefson G, Tran P et al: Olanzapine versus placebo and haloperidol Acute phase results of north American double-blind olanzapine trial. Neuropsychopharmacology 14:111 123, 1996
 
6) Tran PV, Delleva MA, Tollefson GD et al: Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychosis. Br J Psychiatry 172:499-505, 1998
 
7) Beasley CM Jr, Hamilton SH, Crawford AM et al: Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. European Neuropsychopharmacology 7:125-137, 1997
PubMed
8) Tollefson G, Beasley Jr, Tran P et al: Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial. Am J Psychiarty 154:457-465, 1997
 
9) Tran PV, Delleva MA, Tollefson GD et al: Olal olanzapine versus oral haloperidol in the treatment of schizophrenia and related psychosis. Br J Psychiarty 172:499-505, 1998
 
10) Tran PV, Hamilton SH, Kuntz AJ: Double blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. Journal of clinical psychopharmacology 17:407-418, 1997
PubMed
11) 村崎光邦, 小山司, 町山光輝ほか: 新規抗精神病薬塩酸perospironeの精神分裂病に対する臨床評価-長期投与試験-基礎と臨床 31:2207-2230, 1970
 
12) Arato M, O'cornor M, Melzer H: Ziprasidone: efficacy in the prevention of relapse and in the longterm treatment of negative symptoms of chronicschizophrenia. Eur Neuropsychopharmacol 7:S214, 1997
 
13) Prakash A, Lamb HM: Zotepine Areview of its pharmacodynamic and pharmacokinetic propertiesand therapeutic efficacy in the management of schizophrenia. CNS drugs 9:153-175, 1998
 
14) Fujisawa Data on File: Multicentre, double blind, parallel-group comparative study of zotepine versus haloperidol, evaluating costs, quality of life and efficacy in patients with chronic or subchronic schizophrenia.
 
15) Tavcar R, Dernovsek ZM, Zvan V: Choosing antipsychotic maintenance therapy-A naturalistic study. Pharmacopsychiatry 33:66-71, 2000
 
16) Robinson D, Woerner MG, Alvir JM et al: Predictors of relapse following response from a first episode of schizophrenia or shizoaffective disorder. Arch Gen Psychiatry 56:241-247, 1999
PubMed
17) Kane JM: Schizophrenia. N Engl J Med 334:34-41, 1996
PubMed
18) Ohel M, Hummer M, Fleischhacker WW: Compliance with antipsychotic treatment. Acta Psychiatr Scand 102 (Suppl 407):83-86, 2000
 
19) 村崎光邦, 工藤義雄, 小山司ほか: 長期投与におけるフマル酸クエチアピンの精神分裂病に対する有効性および安全性の検討. 臨床精神薬理 2:633-652, 1999
 
20) 諸川由実代: 非定型抗精神病薬治療の世界的動向. 臨床精神薬理 4:1615-1624, 2001
 
21) Peuskens J, Link CGG: A comparison ofquetiqpine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 96:265-273, 1997
 
22) Velligan DI, Newcomer J, Pultz J et al: Improvement in cognitive functioning with long-term quetiapine is superior to haloperidol. Schzophr Res 41:205, 2000
 
P.101 掲載の参考文献
1) Kane J, Honigfeld G, Singer J et al: Clozapine for the treatment-resistant schizophrenic.: a double-blind comparison versus chlorpromazine/benztropine. Arch Gen Psychiatry 45:789-796, 1988
 
2) Claghorn J, Honigfeld G, Abuzzahab FS et al: The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacology 7:377-384, 1987
 
3) 稲垣 中, 藤井康男, 稲田俊也ほか: 日本には clozapineは必要ないのか? 臨床精神薬理 1:315-319, 1998
 
4) 稲垣 中:治療抵抗性分裂病-その概念と治 Schizophrenia Practice 4, 診療新社, 東京, 2001
 
5) 稲垣 中: 将来の日本におけるclozapineの投与対象について. 臨床精神薬理 6:55-64, 2003
 
6) 石郷岡純: 海外におけるclozapineの副作用モニタリングシステム. 臨床精神薬理 6:45-53, 2003
 
7) 八木剛平, 稲垣 中, 山田和男ほか: 治療抵抗性精神分裂病の実態と至適薬物療法に関する研究. 厚生省精神・神経疾患研究委託費精神分裂病の病態, 治療・リハビリテーションに関する研究総括研究報告書, 1998, pp. 97-104
 
8) Essock SM, Hargreaves WA, Dohm FA et al: Clozapine eligibility among state hospital patients. Schizophrenia Bulletin 22:15-25, 1996
PubMed
9) Juarez-Reyes MG, Shumway M, Battle C et al: Efects of stringent criteria on eligibility for clozapine among public mental health clients. Psychiatric Services 46:801-806, 1995
 
10) Quitkin JE, Rifkin A, Klein D: Very high dosage versus standard dosage fluphenazine in schizophrenia: A double-blind study of non-chronic treatment-refractory patients. Arch Gen Psychiatry 32:1276-1281, 1975
 
11) Breier A, Buchanan RW, Kirkpatrick B et al: Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 151:20-26, 1994
PubMed
12) Breier A, Malhotra AK, Su T-P et al: Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am J Psychiatry 156:294-298, 1999
PubMed
13) Emsley RA, Raniwalla J, Bailey PJ et al: A comparison of the effects of quetiapine ('Seroquel) and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. Int Clin Psychopharmacol 15:121-131, 2000
 
14) 稲垣 中: 精神分裂病治療における抗精神病薬の多剤併用に関する日本と諸外国との比較. 臨床精神薬理 4:1381-1388, 2001
 
15) 谷向 弘, 乾 正, 高橋尚武ほか: :重盲検法によるclozapineの精神分裂病に対する薬効検定. 精神医学 15:269-284, 1973
 
16) 八木剛平, 三浦貞則, 田代巌ほか: :重盲検法によるclozapineとhaloperidolの精神分裂病に対する薬効の比較. 臨床評価 2:169-206, 1974
 
17) Breier A, Hamilton SH: Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Biol Psychiatry 45:403-411, 1999
PubMed
18) Azorin J-M, Spiegel R, Remington G et al: A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. Am J Psychiatry 158:1305-1313, 2001
PubMed
19) Volavka J, Czobar P, Sheitman B et al: Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 159:255-262, 2002
 
20) Tollefson GD, Birkett MA, Kiesler GM et al: Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry 49:52-63, 2001
PubMed
21) Bondolfi G, Dufour H, Patris M et al: Risperidone versus clozapine in treatment-resistant chronic schizophrenia: A randomized double-blind study. Am J Psychiatry 155:499-504, 1998
PubMed
22) Conley RR, Tamminga CA, Bartko JJ et al: Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry 155:914-920, 1998
PubMed
23) Wirshing DA, Marshall BD, Green MF et al: Risperidone in treatment-refractory schizophrenia. Am J Psychiatry 156:1374-1379, 1999
PubMed
24) Zhang X-Y, Zhou D-F, Cao L-Y et al: Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study. Int J Clin Psychopharmacol 16:325-330, 2001
 
25) Bitter I, Slabber M, Pretorius J et al: Olanzapine versus clozapine in patients nonresponsive or intolerant to standard acceptable treatment of schizophrenia. XXII nd CINP Congress, July 9-13, Brussels, Belgium, 2000
 
26) Kern RS, Green MF, Marshall BD Jr et al: Risperidone vs. haloperidol on reaction time, manual dexterity, and motor learning in treatment-resistant schizophrenia patients. Biol Psychiatry 44:726-732, 1998
PubMed
27) 稲垣中: 重症治療抵抗性患者への非定型抗精神病薬への適応はあるのか. 臨床精神薬理 2:1371-1373, 1999
 
28) FIynn SW, MacEwan GW, Altman S et al: An open comparison of clozapine and risperidone in treatment-resistant schizophrenia. Pharmacopsychiat 31:25-29, 1998
 
29) Lindenmayer J-P, Iskander A, Park M et al: Clinical and Neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: A prospective study. J Clin Psychiatry 59:521-527, 1998
PubMed
30) Conley RR, Tamminga CA, Kelly DL et al: Treatment-resistant schizophrenic patients respons to clozapine after olanzapine non-response. Biol Psychiatry 46:73-77, 1999
 
31) 藤井康男, 早馬俊, 稲垣中ほか: Risperidoneによる分裂病治療-従来の抗精神病薬からの切り替えと経過追跡-. 臨床精神薬理 1:527-541, 1998
 
32) 前田久雄, 中村純, 辻丸秀策ほか: フマル酸クエチアピンの治療抵抗性精神分裂病に対する臨床効果. 臨床精神薬理 2:653-668, 1999
 
33) 高橋義人, 久住一郎, 伊藤耕一・ほか: 治療抵抗性分裂病-症例報告-. Schizophrenia Practice Vol. 6, 診療新社, 東京, 2002
 
34) 五十嵐潤, 杉原克比古, 橋本和典ほか: Perospirone投与と精神科作業療法の併用が著効した難治性分裂病の1例. 臨床精神薬理 5:1451-1457, 2002
 
35) 宮本洋: 長期間隔離室収容となっていた治療抵抗性精神分裂病に対するペロスピロンの効果について. 精神医学 44:673-676, 2002
 
36) 吉岡正哉: 2種の非定型抗精神病薬で十分な効果を認めず, 塩酸ペロスピロンに変更後, 著明改善を示した精神分裂病入院患者の1例. Prog Med 21:2390-2391, 2001
Medical*Online
37) 内藤明彦: 塩酸ペロスピロンが奏効した精神分裂病慢性難治例. Prog Med 21:1895-1896, 2001
Medical*Online
38) 守屋朝夫: 服薬中断による再燃と各種前薬での治療抵抗性精神分裂病患者に対して塩酸ペロスピロンが奏効した1例. PJ: og Med 21:1895-1896, 2001
 
39) 山田和夫: 塩酸ペロスピロンにて改善した慢性分裂病の2症例. Prog Med 21:1876-1878, 2001
Medical*Online
40) 藤井康男: 治療抵抗性統合失調症患者へのolanzapineの位置づけ-投与量に関する文献的検討-. 臨床精神薬理 6:427-439, 2003
 
41) Lerner V: High-dose olanzapine for treatment-refractory schizophrenia. Clin Neuropharmacol 26:58-61, 2003
PubMed
42) Dursun SM, Gardner DM, Birs DC et al: Olanzapine for patients with treatment-resistant schizophrenia: A naturalistic case-series outcome study. Can J Psychiatry 44:701-704, 1999
 
43) Baldacchino AM, Stubbs JH, Nevison-Andrews D: The use of olanzapine in non-complaint or treatment-resistant clozapine population in hospital. Pharmaceutical Journal 260:207-209, 1998
 
P.110 掲載の参考文献
1) Allen MH, Currier GW, Hughes DH et al: The Expert Consensus Guideline Series: Treatment of Behavioral Emergencies. Expert Knowledge System L. L. C. 2001 (大野裕訳: エキスパートコンセンサスガイドラインシリーズ精神科救急治療. アルタ出版, 東京, 2002)
 
2) American Psychiatric Association: Practice Guideline for the Treatment of Patients with Schizophrenia. Am J Psychiatry 154 (Suppl):1-63, 1997
 
3) Hargreaves S: NICE guidelines address social aspect of schizophrenia. BMJ 326:679, 2003
PubMed
4) Lehman AF, Steinwachs DM, the Co-lnvestigators of the PORT Project: At issue: Translating research into practice: The Schizophrenia Patient Outcomes Research Team (PORT) Treatment Recommendations. Schizophrenia Bulletin 24:1-10, 1998
 
5) McEvoy JP, Scheifler PL, Frances A: The Expert Consensus Guideline Series; Treatment of Schizophrenia l999. Expert Consensus Guidelines L. L C. 1999 (大野裕訳: エキスパートコンセンサスガイドライン精神分裂病の治療 1999. ライフサイエンス, 東京, 2000)
 
6) National Institute for Clinical Excellence: Technology Appraisal Guidance-No. 43: Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. London, June 2002
 
7) Taylor D, Paton C, Kerwin R et al: The Maudsley 2001 Prescribing Guidelines 7th ed Martin Dunitz Taylor & Francis Group, London and New York, 2003
 
P.117 掲載の参考文献
1) Arvanitis LA, Miller BG: the Seroquel Trial 13 Study Group: Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of acute exacerbation of schizophrenia: acomparison with haloperidol and placebo. Biol Psychiatry 42:233-246, 1997
 
2) Beaseley CM, Tollefson G, Tran P et al: Olanzapine versus placebo and haloperidol. Acute phase results of north American double-blind olanzapine trial. Neuropsychopharmacology 14:111-123, 1996
 
3) Beaseley CM, Hamilton SH, Crawford AM et al: Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Psychopharmacol 7:125 137, 1997
 
4) Borison RL, Pathiraja AP, Diamond BI et al: Risperidone: Clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 28:213-218, 1992
PubMed
5) Bymaster FP, Falcone JF: Decreased binding affinity of olanzapine and clozapine for human muscarinic receptors in intact clonal cells in physiological medium. Eur J Pharmacol 390:245-248, 2000
PubMed
6) Copolov DL, Link CGG. Kowalcyk B: Amulticentre, double-blind, randomized comparison of quetiapine (ICI204, 636,: Seroquel) and haloperidol in schizophrenia. Psychol Med 30:95-105, 2000
 
7) Crawford AM, Beasley CM Jr, Tollefson GD: The acute and long-term effect of olanzapine: compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res 26:41-54, 1997
PubMed
8) Emsley RA, Risperidone Working Group: Risperidone in the treatment of first-episode psychotic patients: A double-blind multicenter study. Schizophr Bull 25:721-729, 1999
 
9) Janicak PG, Davis JM, Preskorn SH et al: Principles and Practice of Psychopharmacology. Third edition. Lippincott Williams & Wilkins, Philadelphia, 2001
 
10) 久住一郎, 高橋義人, 小山司: 新規非定型抗精神病薬の薬理特性. Schizophrenia Frontier 2:223- 228, 2001
 
11) Leysen JE, Janssen PMF, Schotte A et al: Serotonin Receptor Subtypes: Possible Roles and Implications in Antipsychotic Drug Action. In Serotonin in Antipsychotic Treatment-Mechanisms and Clinical Practice (ed by: Kane JM, Moller HJ, Awouters F), Marcel Dekker, Inc, New York, 1996, pp. 51-75
 
12) Marder SR, Davis JM, Chouinard G: The effect of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the north American trials. J Clin Psychiatry 58:538-546, 1997
PubMed
13) 村崎光邦, 小山司, 町山幸輝ほか: 新規抗精神病薬塩酸perospironeの精神分裂病に対する臨床評価-haloperidolを対照薬とした第III相試験 Clin Eval 24:207-248, 1997
 
14) 村崎光邦: Perospironeの基礎と臨床. 臨床精神薬理 4:849-868, 2001
 
15) Ohno Y, Ishida-tokuda K, Ishibashi T et al: Effects of perospirone (SM-9018), a potential atypical neuroleptics, on dopamine D1 receptor-mediated vacuous chewing movement in rats: A role of 5-HT2 receptor blocking activity. Pharmacol Biochem Behav 57:889-895, 1997
PubMed
16) Shotte A, Janssen PF, Gommeren W et al: Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124:57-73, 1997
 
17) Tollefson GD, Beasley CM, Tran PV et al: Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and Schizophreniform disorders: Results of an intemational collaborative trial. Am J Psychiatry 154:457
 
18) 融道男: 向精神薬マニュアル第:版. 医学書院, 東京, 2001
 
19) 山口高史, 中澤隆弘, Bymaster FP: Multi-Acting Receptor Targeted Antipsychotic (MARTA) とは- Olanzapineの薬理特性と臨床効果一. 臨床精神薬理 4:919-930, 2001
 

PART 3 新規抗精神病薬を用いた臨床例

P.123 掲載の参考文献
1) 上田均, 酒井明夫: スイッチングとコンプライアンスの向上. 臨床精神薬理 5:371-379, 2002
 
2) 上田均, 及川暁, 酒井明夫: 急性期における使い分け. 臨床精神薬理 5:1027-1035, 2002
 
P.127 掲載の参考文献
1) Allen M H: Managing the agitated psychotic patient. A reappraisal of J Clin Psychiatry 61 (Suppl 14):ll-20, 2000
 
2) Allen M H: 激越性精神病患者マネージメント法の進歩. 臨床精神薬理 3:1203-1210, 2000
 
3) 南光進一郎, Currier G W, Conley R et al: Round Table Discussion. 臨床精神薬理 4:1697-1707, 2001
 
4) 大下隆司: 急性期精神病患者へのアプローチ. 臨床精神薬理5 (増刊):311-321, 2002
 
P.130 掲載の参考文献
1) 生駒幸弘, 赤井哲夫, 仲田行恵ほか: 麦角アルカロイド誘導体テルグリドの中枢神経への影響: 生化学的及び行動薬理学的検討. 日本薬理学雑誌 102:113-129, 1993
 
2) 中山和彦, 勝 久寿: 性ホルモンと気分障害関連障害 (更年期障害を含む). 臨床精神医学 27:1105-1112, 1998
 
3) Svensson K, Eriksson E, Carlsson A: Partial dopamine receptor agonists reverse behavioral, biochemical and neuroendocrine effects of neuroleptics in the rat: potential treatment of extrapyramidal side effects. Neuropharmacology 32:1037-1045, 1993
PubMed
4) Filip V, Marsalek M, Halkova E et al: Treatment of extrapyramidal side effects with terguride. Psychiatry Research 41:9-16, 1992
PubMed
5) Allison DB, Mentore JL, Heo M et al: Antipsychotic-induced wait gain: A comprehensive research synthesis. Am J Psychiatry 156:1686-1696, 1999
 
6) Golda V: Ambient effect of long lasting terguride treatment on genetically based glycide and lipid metabolism abnormalities in SHR/N-cp Koletsky rats. Acta Medica 41:81-85, 1998
 
P.134 掲載の参考文献
1) 小山司, 井上猛, 高橋義人ほか: 治療抵抗性精神分裂病に対するolanzapine長期投与時の臨床効果. 臨床精神薬理 4:109-125, 2001
 
2) Lemer V: High-dose olanzapine for treatment-refractory schizophrenia. Clinical Neuropharmacology 26:58-61, 2003
 
3) Lindenmayer JP, Czobor R Vblavka J et al: 0lanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open label switch study. J Clin Psychiatry, 63:931-935, 2002
PubMed
4) Taylor D, Refractory schizophrenia: evidence-based treatment. Pharm Journal 263 (Suppl 1):2-3, 1999
 
5) Tollefson GD, Birkett MA, Kiesler GM et al: Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry 49:52-63, 2001
PubMed
P.139 掲載の参考文献
1) 内藤宏, 織田直久, 伊藤光泰ほか: 非定型抗精神病薬による肥満, 耐糖能障害と糖尿病性ケトアシドーシス. 臨床精神医学 32:489-499, 2003
Medical*Online
2) 中根允文: 統合失調症患者と糖尿病. 臨床精神薬理 6:751-766, 2003
 
P.141 掲載の参考文献
1) 佐々木幸哉, 角南智子, 井上誠士郎ほか: せん妄に対するquetiapineの使用経験. 第24回日本生物学的精神医学会プログラム・講演抄録:289, 2002
 
2) 佐々木幸哉, 傳田健三, 小山司: Quetiapineが著効したせん妄の3症例. 精神医学 43: 1253-1255, 2001
 
P.143 掲載の参考文献
1) Glassman AH, Bigger JT Jr: Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 158:1774-1782, 2001
PubMed
2) 定永恒明, 定永史子, 八尾博史: 向精神薬と心電図QTc時間延長もしくはTorsades de pointesについて. 精神医学 43:921-921, 2001
 
P.145 掲載の参考文献
1) 長嶺敬彦: 新規抗精神病薬と高脂血症. 臨床精神薬理 5:1421-1427, 2002
 
2) 長嶺敬彦: 精神病院入院患者における高脂血症の頻度. 精神医学 43:1263-1268, 2001
 
P.148 掲載の参考文献
1) 伊賀淳一, 吉松誠, 前田正人: Perospironeにより著明改善し目覚め現象を経て退院した治療抵抗性分裂病の1症例. 精神医学 44:261-264, 2002
 

PART 4 治療上の注意点

P.160 掲載の参考文献
1) 上島国利, 津村哲彦: 精神科外来薬物療法の問題点. 精神経誌 83:691-699, 1981
 
2) 伊藤斉, 藤井康男: 向精神薬の併用の実態とメリット, デメリットの論議をめぐって. 神経精神薬理 5:149-184, 1983
 
3) 稲垣中: 精神分裂病治療における抗精神病薬の多剤併用に関する日本と諸外国との比較. 臨床精神薬理 4:1381-1388, 2001
 
4) 稲垣中, 不破野誠一, 福田真道ほか: 国立精神病院に入院中の分裂病患者における抗精神病薬の処方実態. 第11回日本臨床精神神経薬理学会 (学会抄録), 広島, 2001, pp. 21
 
5) 稲垣中, 冨田真幸: 日本における新規抗精神病薬と多剤大量処方. 臨床精神薬理 6:391-401, 2003
 
6) 宮本聖也, 大木美香: 抗精神病薬の選択と多剤併用. 臨床精神薬理 5:1633-1641, 2002
 
7) 稲垣中, 稲田俊也, 藤井康男ほか: 向精神薬の等価換算表. 星和書店, 東京, 2000
 
8) Aoba A, Mulholland L: Current issues in the psychopharmacology of schizophrenia in Japan. In: Current Issues in the Psychopharmacology of Schizophrenia (ed. by Breier A, Tran P V, Herrea J M et al), Lippincott Williams & Wilkins, Philadelphia, 2001, pp. 544-555
 
9) 青葉安里, 山口登, 太田共夫ほか: 定型抗精神病薬から非定型抗精神病薬への国際的展開-我が国の現状を踏まえて-. 臨床精神薬理4:899-911, 2001
 
10) 藤井康男: 多剤併用から新しい抗精神病薬治療へ. 臨床精神薬理 4:1371-1379, 2001
 
11) 風祭元: 我が国の精神科医療における長期大量多剤投与とその副作用. 精神医学 39:1181-1187, 1997
 
12) 大森哲郎: 向精神薬の併用: 有効な場合と有害な場合. 臨床精神医学 30:1071-1076, 2001
Medical*Online
13) Lieberman JA: Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. J Clin Psychiatry 57 (Suppl 11):68-71, 1996
 
14) Miyamoto S, Duncan GE, Mailman RB et al: Developing novel antipsychotic drugs: strategies and goals. Curr Opin CPNS Invest Drugs 2:25-39, 2000
 
15) Miyamoto S, Duncan GE, Goff DC et al: Therapeutics of Schizophrenia. In Neuropsychophamacology: The Fifth Generation of Progress (ed. by Davis KL, Chamey D, Coyle JT et al), Lippincott Williams & Wilkins, Philadelphia, 2002, pp. 775-807
 
16) Miyamoto S, Duncan GE, Aoba A et al: Acute pharmacologic treatment of schizophrenia. In: Schizophrenia (ed. by Hirsch SR, Weinberger DR), Blackwell Science Ltd, London, 2003, pp. 442-473
 
17) Miyamoto S, Lieberman JA, Fleishhacker WW et al: Antipsychotic drugs. In: PSYCHIATRY (Second edition) (ed. by Tasman A, Kay J, Lieberman JA), John Wiley & Sons, Ltd, London, 2003, pp. 1928-1964
 
18) 宮本聖也, Lieberman JA, 青葉安里: 第二世代抗精神病薬による急性期治療のあり方. 臨床精神薬理 4:1633-1641, 2001
 
19) 青葉安里, 宮本聖也: 新規抗精神病薬の光と影. 臨床精神薬理 5:1375-1389, 2002
 
20) Kapur S, Remington G: Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153:466-476, 1996
PubMed
21) Schotte A, Janssen PFM, Gommeren W et al: Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124:57-73, 1996
 
22) Miyamoto S, Duncan GE, Lieberman JA: Second generation antipsychotics: Olanzapine. In: Current Issues in the Psychopharmacology of Schizophrenia (ed. by Breier A, Tran PV, Herrera J et al), Lippincott Williams & Wilkins Healthcare, Philadelphia, 2001, pp. 224-242
 
23) American Psychiatric Association: Practice guideline for the treatment of patients with schizophrenia. In: Practice Guidelines for the Treatment of Psychiatric Disorders, American Psychiatric Association, Washington D. C., 2000, pp. 299-412
 
24) McEvoy JP, Scheifler PL, Frances A: The expert consensus guideline series: Treatment of schizophrenia 1999. J Clin Psychiatry 60 (Suppl 11):4-80, 1999
 
25) Miller AL, Chiles JA, Chiles JK et al: The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms. J Clin Psychiatry 60:649-657, 1999
PubMed
26) Covell NH, Jackson CT, Evans AC et al: Antipsychotic prescribing Practices in connecticut's public mental health system: rates of changing medications and prescribing styles. Schizophr Bull 28:17-29, 2002
PubMed
27) 石郷岡純, 吉岡正哉: 精神分裂病におけるQOL (quality of life) の改善をめざした薬物療法. 臨床精神薬理 5:3-13, 2002
 
28) 藤井康男, 福田真道: 新しい抗精神病薬導入に伴う分裂病薬物治療の変化. 精神科治療学 16:1243-1251, 2001
 
29) 諸川由美代: 非定型抗精神病薬-SDA-の社会復帰に果たす役割. 臨床精神薬理 4:317-324, 2001
 
30) Marder SR, Essock SM, Miller AL et al: The Mount Sinai Conference on the pharmacotherapy of schizophrenia. Schizophrenia Bull 28:5-16, 2002
 
31) 大森哲郎: 従来型抗精神病薬および新規非定型抗精神病薬の役割分担と使い分け. 臨床精神薬理 5:1019-1026, 2002
 
32) Remington G, Kapur S: D2 and 5-HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PET. J Clin Psychiatry 60 (Suppl 10):15-19, 1999
 
33) Nyberg S, Farde L: Non-equipotent doses partly explain differences among antipsychotics-implications of PET studies. Psychopharmacology (Berl) 148:22-23, 2000
PubMed
34) Kapur S, Zipursky R, Jones C et al: Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 157:514-520, 2000
PubMed
35) Waddington JL, Kapur S, Remington GJ: The neuroscience and clinical psychopharmacology of first and second-generation antipsychotic drugs. In: Schizophrenia (ed. by Hirsch SR, Weinberger DR), Blackwell Science Ltd, London, 2003, pp. 421-441
 
36) Farde L, Nyberg S, Oxenstierna G et al: Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients. J Clin Psychopharmacol 15 (Suppll) :19S-23S, 1995
PubMed
37) Nyberg S, Eriksson B, Oxenstierna G et al: Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Am J Psychiatry 156:869-875, 1999
PubMed
38) Stahl SM: Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials. J Clin Psychiatry 60:31-41, 1999
PubMed
39) 三木和平, 荘司美香, 大谷健ほか: 急性期の精神分裂病患者に対するrisperidone 単剤投与の効果. 臨床精神薬理 5:1115-1125, 2002
 
40) Kapur S, Zipursky RB, Remington G et al: 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatrv 155:921-928, 1998
 
41) Gefvert O, Lundberg T, Wieselgren I-M et al: D2 and 5HT2A receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. Eur. Neuropsychopharmacol 11:105-110, 2001
PubMed
42) Gefvert O, Bergstrom M Langstrom B et al: Time course of central nervous dopamine D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology (Berl) 135:119-126, 1998
PubMed
43) Kapur S, Zipursky R, Jones C et al: A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 57:553-559, 2000
 
44) Williams R: Optimal dosing with risperidone: updated recommendations. J Clin Psychiatry 62:282-289, 2001
PubMed
45) Laruelle M, Abi-Dargham A, Gil R et al: Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry 46:56-72, 1999
PubMed
46) Levinson DF, Singh H, Simpson GM: Timing of acute clinical response to fluphenazine. Br J Psychiatry 160:365-371, 1992
PubMed
47) Levinson DF, Simpson GM, Lo E-S et al: Fluphenazine plasma levels, dosage, efficacy, and side effects. Am J Psychiatry 152:765-771, 1995
PubMed
48) Marder SR, Meibach RC: Risperidone in the treatment of schizophrenia. Am J Psychiatry 151:825-835, 1994
PubMed
49) Chouinard G, Jones B, Remington G et al: A Canadian multicenter placebo Controlled study of fixed doses of risperidone and haloperidol in the treatmentof chronic schizophrenic patients. J Clin Psychopharmacol 13:25-40, 1993
 
50) 藤井康男: 分裂病薬物治療の新時代. ライフ・サイエンス, 東京, 2000
 
51) Beasley Jr CM, Sanger T, Satterlee W et al: Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 124:159-167, 1996
 
52) 宮本聖也: 非定型抗精神病薬による急性期治療が成功した統合失調症 (精神分裂病) の再発激越例. PSYSICIANS THERAPY MANUAL 9:9-10, 2002
 
53) Borison RL, Arvanitis LA, Miller BG: ICI 204, 636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group. J Clin Psychopharmacol 16:158-169, 1996
 
54) 村崎光邦, 小山司, 町山幸輝ほか: 新規抗精神病薬塩酸perospironeの精神分裂病に対する臨床評価-haloperidolを対照薬とした第III相試験. 臨床評価 24:159-205, 1997
 
55) Alphs LD, Summerfelt A, Lann H et al: The negative symptom assessment: a new instrument to assess negative symptoms of schizophrenia. Psychopharmacol Bull 25:159-163, 1989
PubMed
56) Andreasen NC: Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry: 39:784-788, 1982
PubMed
57) 宮本聖也: 新世代の抗精神病薬による精神分裂病の治療:従来薬から非定型抗精神病薬への切り替えをいかに成功させるか? PSYCHO TOPICS 135:1-3, 2002
 
58) 鈴木健文, 高野晴成, 渡邊衡一郎ほか: 精神病薬の多剤併用大量療法への対応ガイドライン. 臨床精神薬理 4:1423-1430, 2001
 
59) 上田均, 酒井明夫: 従来型抗精神病薬からrisperidoneへの切り換え: その4. 臨床精神薬理 4:1709-1721, 2001
 
60) Weiden PJ, Aquila R, Dalheim L et al: Switching antipsychotic medications. J Clin Psychiatry 58 (Suppl 10):63-72, 1997
 
61) Weiden PJ, Aquila R, Emanuel M et al: Long-term considerations after switching antipsychotics. J Clin PSychiatry 59 (Suppl 19):36-49, 1998
 
62) 宮本歩, 長尾喜代治, 長尾喜一郎ほか: 精神分裂病患者におけるrisperidoneからquetiapineへの切り替えについて. 臨床精神薬理 4:1433-1440, 2001
 
63) 伊藤雅之, 丹羽真一, 松本出: 精神分裂病患者におけるrisperidoneからolanzapineへの切り替え -Quality of lifeの向上を目指して. 臨床精神薬理5 (増刊):415-426, 2002
 
64) 宮本歩, 山田恒, 長尾喜代治ほか: 従来型抗精神病薬からquetiapineへの切り替えについて. 臨床精神薬理 5:71-80, 2002
 
65) 宮本歩: 精神分裂病患者におけるquetiapine 24週間投与と経過観察. 臨床精神薬理 5:1127-1145, 2002
 
66) 岩崎剛士, 丹羽真一, 松本出: 統合失調症患者におけるrisperidoneからquetiapineへの2段階増量法による切り替え. 臨床精神薬理6:593-603, 2003
 
67) Stahl SM: Antipsychotic polypharmacy, part 2: tips on use and misuse. J Clin Psychiatry 60:506-507, 1999
PubMed
68) 宮本聖也, 青葉安里: 抗精神病薬の新薬開発の未来. 月刊薬事 44:57-62, 2002
 
P.170 掲載の参考文献
1) 石郷岡純: 生涯薬物 (抗精神病薬) 療法, 新世紀の精神科治療1統合失調症の診療学, 岡崎祐士編, 中山書店, 東京, 2002, pp. 275-287
 
2) 石郷岡純: 新規抗精神病医薬の開発の歴史と今後の動向. 脳の科学 25:425-436, 2003
 
3) 石郷岡純: 単剤療法 (monotherapy) からskilful polypharmacyへ. Schizophrenia Frontiet:2:234-238, 2001
 
4) 石郷岡純, 吉岡正哉: 精神分裂病におけるQOL (quality of life) の改善をめざした薬物療法. 臨床精神薬理 5:3-13, 2002
 
5) 藤井康男: 21世紀の抗精神病薬療法-Olanzapine vs risperidone. 臨床精神薬理 4:1103-1110, 2001
 
6) 宮本聖也, 大木美香: 抗精神病薬の選択と多剤併用. 臨床精神薬理 5:843-854, 2002
 
7) Lambert T: 共通の治療目標: 抗精神病薬の切り替え. 臨床精神薬理 5:465-472, 2002
 
P.176 掲載の参考文献
1) Allen MH, Currier GW, Hughes DH et al (大野裕訳): Treatment of behavioral emergencies, アルタ出版, 東京, 2002, pp. 48-63
 
2) Glenn W, Cunier MD, George M et al: Risperidone liquid concentrate and oral lorazepam versus intramuscular Haloperidol and intramuscular Lorazepam for treatment of psychotic agitation. J Clin Psychiatry 62:153-57, 2001
 
3) Aleman A, Kahn RS: Effects of the antipsychotic risperidone on hostility and aggression in schizophrenia: a meta-analysis of controlled trials. EurNeuropsychopharmacol 11:289-293, 2001
PubMed
4) Currier GW: Atypical antipsychotic medication in the psychiatric emergency service. J Clin Psychiatry 14 (Suppl) :21-26, 2000
 
5) 山根秀夫, 増井晃, 山田尚登ほか: リスペリドンが奏効した精神運動興奮をともなう精神分裂病の3例. 臨床精神薬理 5:725-732, 2002
 
6) Jacicak PG, Keck PE, Davis JM, et al: Adouble-blind, randomized, prospective evaluation of the efficacy and safty of risperidone versus haloperidol in the treatment of schizoaffective disorder. J Clin Psychopharmacol 21:360-368, 2001
 
7) 村崎光邦, 小山司, 町山光輝ほか: 新規抗精神病薬塩酸perospironeの精神分裂病に対する臨床評価-haloperidolを対照薬とした第m相試験Clin Eval 24:159-205, 1997
 
8) Hellewell J, Cantillon M, Mckeller M et al: seroquel: : efficacy in aggression, hostility and low mood of schizophrenia. Int. Neuropsychopharmacol 2 (Suppl 1):S 112, 1999
 
9) 前田久雄, 中村純, 辻丸秀策ほか: フマル酸クエチアピンの治療抵抗性精神分裂病に対する臨床効果. 臨床精神薬理 2:653-668, 1999
 
10) Gomez JC, Crawford AM: Superior Efficacy of Olanzapine Over Haloperidol: Analysis of Patients With Schizophrenia from a multicenter international trial. J Clin Psychiatry 62:6-11, 2001
 
11) 宮本聖也: 非定型抗精神病薬による急性期治療が成功した統合失調症の再発激越例. Physicians therapy manual 9:2002
 
12) Tohen M, Jacobs TG, Grundy SL et al: Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzapine HGGW Study Group. Arch Gen Psychiatry 59:841-849, 2000
 
13) James RH: Emergency treatment of acute psychosis. J Clin Psychiatry 59 (Suppl 1):57-61, 1998
 
14) Zafar AS: Common treatment goals of antipsychotics; Acute treatment. J Clin Psychiatry 59 (Suppl 19):5-8, 1998
 
15)中川博畿: Risperidoneによる急性期治療. 臨床精神薬理 5:612-618, 2002
 

PART 5 安全性とQOL

P.183 掲載の参考文献
1) 畑田けい子, 中根允文: QOL, 満足度などの評価法臨床精神医学講座別巻1精神科データブック (中根允文・浅井昌弘編), 中山書店, 東京, 2001, pp.301-314
 
2) 丸山晋, 武藤正樹, 今中雄一ほか: 平成5年度厚生科学研究分担研究報告書「精神医療における QOLの評価に関する研究」, 1994, pp.1-50
 
3) 尾藤誠司: QOLの評価. 精神科診断学 9:13-21, 1998
 
4) Tran PV, Bymaster FP, Tye N et al: Olanzapin (Zyprexa): A novel antipsychotic, Lippincott Williams & Wilkins Healthcare, PA, USA, 1999 (村崎光邦監訳: オランザピン, MIT, 東京, 2001)
 
5) 宮田量治: 薬物療法の実際: 新薬とQOLの改善. 精神科治療学 16:1267-1278, 2001
 
6) Kleinman L, Revicki DA: 精神分裂病における QOL評価, (徳山まどか・武田雅俊 訳) Schizophrenia Frontier 2:119-128, 2001
 
7) 中根允文 (監修): 精神疾患とQOL, メディカル・サイエンス・インターナショナル, 東京, 2002 (Katschnig H, Freeman H, Sartorius N eds,: Quality of Life in Mental Disorders, John wiley & Sons Ltd, Chichester, 1997)
 
8) Orley J, Kuyken w (eds.): Quality of Life Assessment: International Perspectives, Springer-Verlag, Berlin, 1994
 
9) Mapi Research Institute: Cultural adaptation of quality of life (QOL) instruments. Quality of Life Newsletter 18:10-11, 1997
 
10) 福原俊一: MOS Short-Form 36-ltem Health Survey: 新しい患者立脚型健康指標, 厚生の指標 46:40-45, 1999
 
11) 日本語版EuroQoL開発委員会: 日本語版EuroQoLの開発, 医療と社会 8:109-123, 1998
 
12) Division of Menrtal Health, WHO: Quality of life assessment. An annotated bibliography. WHO, Geneva, 1994
 
13) Division of Menrtal Health, WHO: WHOQOL: Measuring Quality of Life. WHO, Geneva, 1997
 
14) 田崎美弥子, 野地有子, 中根允文: WHOのQOL 診断と治療 83:2183-2198, 1995
Medical*Online
15) WHOQOL Group: Development of the world Health Organization WHOQOL-Bref Quality of life assessment. Psychol Med 28:551-558, 1998
PubMed
16) 田崎美弥子, 中根允文: WHOQOL短縮版-使用手引き, 金子書房, 東京, 1997
 
17) 中根允文, 田崎美弥子, 宮岡悦良: 一般人口におけるQOLスコアの分布-WHOQOLを利用して-, 医療と社会 9:123-131, 1999
 
18) 宮田量治, 藤井康男 (訳): クオリティ・オブ・ライフ評価尺度-解説と利用の手引, 星和書店, 東京, 1995
 
19) Wilkinson G, Hesdon B, Wild D et al: Self-report quality of life measure for people with schizophrenia: the SQLS. Brit J Psychiatry 177:42-46, 2000
 
20) Kaneda Y, Imakura A, Fujii A et al: Schizophrenia quality of life scale: validation of the Japanese version. Psychiatry Res 113:107-113, 2002
PubMed
21) 兼田康宏・谷口隆英・石元康仁ほか: 非定型抗精神病薬のQOLに及ぼす影響についての検討, 精神薬療研究年報 34:93-99, 2002
 
22) Bobes J, Gonzalez MP: Quality of life in schizophrenia. In: Quality of Life in Mental Disorders, ed. by Katchnig H, Freeman H, Sartorius N. 1997 (文献7を参照)
 
23) Bobes J: Current status of quality of lise assessment in schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 251 (Suppl II): II/38-II 42, 2001
 
24) Gaite L, Vazquez-Barquero JL, Arrizabalaga AA et al: Quality of life in schizophrenia: development, reliability and internal consistency of the Lancashire Quality of Life Profile-European version. Brit Psychiatry 177 (Suppl 39):s49-s54, 2000
 
25) 中根允文: 精神障害者におけるQOL評価の研究 (11470202), 平成11・12年度科学研究費補助金研究成果報告書基盤研究 (B) (2), 2001
 
26) RitsnerM, Ponizovsky A, Endicott J et al: The impact of side-effects of antipsychotic agents on life satisfaction of schizophrenia patients: a naturalistic study. Eur Neuropsychopharmacol 12:31-38, 2002
 
27) Awad AG, Hogan TP: Subjective response to neuroeptics and the quality of life: Implication for treatment outcome. Acta Psychiatr Scand 89 (Suppl 380), 27-32, 1994
 
28) Awad AG, Voruganti LN, Heslegrave RJ: A conceptual model of quality of life in schizophrenia: description and preliminary clinical validation Qual Life Res 6:21-26, 1997
PubMed
29) Franz M, Lis L, Pluddemann K et al: Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients. Br J Psychiatry 170:422-425, 1997
 
30) Tollefson GD, Beasley CM Jr, Tran PV et al: Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 154:457-465, 1997
PubMed
31) Voruganti L, Cortese L, Oyewumi L et al: Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective toler-ability, side-effect profile and impact on quality of life. Schizophrenia Res 43:135-145, 2000
 
32) Cook PE, Goldberg JO, van Lieshout RJ: Benefits of switching from typical to atypical antipsychotic medications: a longitudinal study in a community-based setting. Can J Psychiatry 47:870-874, 2002
 
33) Ritchie CW, Chiy E, Harrigan S et al: The impact upon extra-pyramidal side-effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia. In J Geriatr Psychiatry 18:432-440, 2003
 
34) Meltzer HY, Burnett S, Bastani B et al: Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hospital Community Psychiatry 41:892-897, 1990
PubMed
35) Brier A, Buchanan R, Kirkpatrick B et al: Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 151 :20-26, 1994
 
36) Iskedjian M, Hux M, Remington GJ: The Canadian experience with risoeridone for the treatment of schizophrenia: an overview. J Psychiatry, Neurosci 23:229-239, 1998
PubMed
37) Tran PV, Hamilton SH, Kuntz AZ et al: Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacology 17:407-418, 1997
 
38) Mahmoud R, Engelhart L, Oster G: Risperidon vs. conventional antipsychotics: A prospective randomized aturalistic effectiveness trial of outcomes in chronic schizophrenia. Presented at the 36th Annual Meeting of the American College of Neuropsychopharamacology, Kanuela, Hawaii, Dec. 1997
 
39) Rosenheck R, Tekell J, Peters P et al: Does participation in psychosocial treatment augment the benefit of clozapine? Arch Gen Psychiatry 55:618-625, 1998
 
40) Revicki DA, Genduso LA, Hamilton SH et al: Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial. Qual Life Res 8:417-426, 1999
PubMed
41) Horo JM, Edgell ET, Jones PB et al: The European schizophrenia outpatient health outcomes (SOHO) study: rationale, methods and recruitment. Acta Psychiatr Scand 107:222-232, 2003
 
42) Hamilton SH, Revicki DA, Genduso LA et al: Olanzapine versus placebo and haloperidol: quality of life and efflcacy results of the North American double-blind trial. Neuropsychopharmacology 18:41-49, 1998
PubMed
43) 藤井康男, 宮田量治, 村崎光邦ほか: 精神分裂病通院患者へのolanzapine長期投与: QOLを含んだ多様な治療成果検討. 精神薬理 3:1083-1096, 2000
 
P.191 掲載の参考文献
1) Kissling W: The current unsatisfactory state of relapse prevention in schizophrenic psychosis: suggestions for improvement. Clin Neuropharmacol 14 (Suppl 2) :S33-S44, 1991
 
2) Weiden PJ, Olfson M: Cost of relapse in schizophrenia. Schizophrenia Bull 21:419-429, 1995
PubMed
3) Fleischhacker WW, Meise U, Gunther V et al: Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatrica Scand 89 (Suppl 382):S11-S15, 1994
 
4) Gerlach J: Depot neuroleptics in relapse prevention: advantages and disadvantages. Int Clin Psychopharmacol 9 (Suppl 5):S17-S20, 1995
 
5) Kissling W: Compliance. quality assurance and standards for relapse prevention in schizophrenia. Acta Psychiatrica Scand 89 (Suppl 382):S16-S24, 1994
 
6) 山田和男: 抗精神病薬のコンプライアンス. 臨床精神薬理 4:571-577, 2001
 
7) Kelly GR, Mamon JA, Scott JE: Utility of the health belief model in examining medication compliance among psychiatric outpatients. Soc Sci Med 25:1205-1211, 1987
PubMed
8) Buchanan A: A two-year prospective study of treatment compliance in patients with schizophrenia. Psychol Med 22:787-797, 1992
 
9) Lysaker P, Bell M: Insight and cognitive impairment in schizophrenia. Nerv Ment Dis 182:656-660, 1994
PubMed
10) McEvoy JP, Freter S, Everett G et al: Insight and the clinical outcome of schizophrenic patients. J Nerv Ment Dis 177:48-51, 1989
PubMed
11) Bartels SJ, Drake RE, Wallach MA et al: Characteristic hostility in schizophrenic outpatients. Schizophrenia Bull 17:163-171, 1991
PubMed
12) 山田和男:精神分裂病外来患者における服薬不全の評価尺度を用いた臨床経過の検討. 慶應医学 77:157-169, 2000
 
13) Kapur S, Remington G: Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu Rev Med 52:503-517, 2001
PubMed
P.198 掲載の参考文献
1) Guthrie SK: Clinical issues associated with maintenance treatment of patients with schizophrenia. Am J Health Syst Pharm 59 (17 Supp15) :S19-24, 2002
 
2) Leucht S, Pitschel-Walz G, Abraham D et al: Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 5:51-68, 1999
 
3) Sussman N: Choosing an a typical antipsychotic. Int Clin Psychopharmacol 17 (Supp13):S29-33, 2002
 
4) Glazer WM: Expected incidence of tardive dyskinesia associated with atypical antipsychotics. J Clin Psychiatry 61 (Suppl 4):21-26, 2000
 
5) Casey DE: Tardive dyskinesia and atypical antipsychotic drugs. Schizophr Res 35 (Suppl):S61-66, 1999
 
6) Bhana N, Foster RH, Olney R et al: Olanzapine: an updated review of its use in the management of schizophrenia. Drugs 61:111-161, 2001
PubMed
7) Citrome L, Volavka J, Czobor P et al: Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatr Sev 52:1510-1514, 2001
 
8) Simpson MM, Goetz RR, Devlin MJ et al: Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods. J Clin Psychiatry 62:694-700, 2001
PubMed
9) Conley RR, Mahmoud R: A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder Am J Psychiatry, 158:765-774, 2001
PubMed
10) Wirshing DA, Wirshing WC, Kysar L et al: Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 60:358-363, 1999
PubMed
11) Wetterling T: Bodyweight gain with atypical antipsychotics. A comparative review. Drug Saf 24:59-73, 2001
PubMed
12) Allison DB, Mackell JA, McDonnell DD: The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr Serv 54:565-567, 2003
PubMed
13) Volavka J, Czobor P, Sheitman B et al: Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 159:255-262, 2002
PubMed
14) Czobor P, Volavka J, Sheitman B et al: Antipsychotic-induced weight gain and therapeutic response: a differential association. J Clin Psychopharmacol 22:244-451, 2002
PubMed
15) Sernyak MJ, Leslie DL, Alarcon RD et al: Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 159:561-566, 2002
PubMed
16) Koro CE, Fedder DO, L'Italien GJ et al: Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. Bull:325:243, 2002
 
17) Henderson DC: Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS Drugs 16:77-89, 2002
PubMed
18) Newcomer JW, Haupt DW, Fucetola R et al: Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 59:337-345, 2002
PubMed
19) Melkersson KI, Hulting AL, Brismar KE: Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 61:742-749, 2000
PubMed
20) Ryan MC, Collins P, Thakore JH: Impaired fasting glucose tolerance in first episode, drug-naive patients with schizophrenia. Am J Psychiatry 160:284-289, 2003
PubMed
21) Sasaki J, Funakoshi M, Arakawa K: Lipids and apolipoproteins in patients treated with major tranquilizers. Clin pharmacol Ther 37:684 687, 1985
 
22) Wirshing DA, Boyd JA, Meng LR et al: The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 63:856-865, 2002
 
23) Koro CE, Fedder DO, L'Italien GJ et al: An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 59:1021-1026, 2002
PubMed
24) Meyer JM: A retrospective comparison of weight, lipid, and glucose changes between risperidone-and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry 63:425-433, 2002
 
25) Centorrino F, Price BH, Tuttle M et at: EEG abnormalities during treatment with typical and atypical antipsychotics. Am J Psychiaty 159:109-1015, 2002
 
26) Glassman AH, Bigger JT Jr: Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 158:1774-1782, 2001
PubMed
27) Stimmel GL, Gutierrez MA, Lee V: Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia. Clin Ther 24:21-37, 2002
PubMed
28) David SR, Taylor CC, Kinon BJ et al: The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther 22:1085-1096, 2000
PubMed
29) Kleinberg DL, Davis JM, de Coster R et al: Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 19:57-61, 1999
 
P.204 掲載の参考文献
1) Fang J, Bourin M, Baker GB: Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P4502D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol 359:147-151, 1999
 
2) Yasui-Furukori N, Mihara K, Kondo T et al: Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxy-risperidone in Japanese patients with schizophrenia. J Clin pharmacol 43:22-127, 2003
 
3) Yasui-Furukori N, Hidestrand M, Spina E et al: Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. DrugMetab Dispos 29:1263-1268, 2001
 
4) Scordo MG, Spina E, Facciola G et al: Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology 147:300-305, 1999
PubMed
5) Roh HK, Kim CE, Chung WG et al: Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients. Eur J Clin Pharmacol 57:671-675, 2001
PubMed
6) Yasui-Furukori N, Kondo T, Mihara K et al: Lack of correlation between the steady-state plasma concentrations of haloperidol and risperidone. J Clin Pharmacol 42:1083-1088, 2002
PubMed
7) Crewe HK, Lennard MS, Tucker GT et al: The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 34:262-265, 1992
PubMed
8) Spina E, Avenoso A, Facciola G et al: Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine. Ther Drug Monit 23:223-227, 2001
PubMed
9) Spina E, Avenoso A, Scordo MG et al: Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. J Clin Psychopharmacol 22:419-423, 2002
PubMed
10) Ono S, Mihara K, Suzuki A et al: Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes. Psychopharmacology 162:50-54, 2002
PubMed
11) Spina E, Scordo MG, Avenoso A et al: Adverse drug interaction between risperidone and carbamazepine in a patient with chronic schizophrenia and deficient CYP2D6 activity. J Clin Psychopharmacol 21:108-109, 2001
 
12) Takahashi H, YOshida K, Higuchi H et al: Development of parkinsonian symptoms after discontinuation of carbamazepine in patients concurrently treated with risperidone: two case reports. Clin Neuropharmacol 24:358-360, 2001
PubMed
13) Jover F, Cuadrado JM, Andreu L et al: Reversible coma caused by risperidone-ritonavir interaction. Clin Neuropharmacol 25:251-253, 2002
PubMed
14) Kelly DV, Beique LC, Bowmer MI: Extrapyramidal symptoms with ritonavir/indinavir plus risperidone. Ann Pharmacother 36:827-830, 2002
PubMed
15) Lucas RA, Gilfillan DJ, Bergstrom RF: A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism. Eur J Clin Pharmacol 54:639-643, 1998
PubMed
16) Olesen OV, Linnet K: Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication. Ther Drug Monit 21:87-90, 1999
PubMed
17) Linnet K, Olesen OV: Free and glucuronidated olanzapine serum concentrations in psychiatric patients: influence of carbamazepine comedication. Ther Drug Monit 24:512-517, 2002
PubMed
18) Markowitz JS, Devane CL, Liston HL et al: The effects of probenecid on the disposition of risperidone and olanzapine in healthy volunteers, Clin Pharmacol Ther 71:30-38, 2002
PubMed
19) Kashuba AD, Nafziger AN, Keams GL et al: Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. Clin pharmacol Ther 64:257-268, 1998
 
20) Weigmann H, Gerek S, Zeisig A et al: Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 23:410-413, 2001
PubMed
21) Hiemke C, Peled A, Jabarin M et al: Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects. J Clin Psychopharmacol 22:502-506, 2002
PubMed
22) Gex-Fabry M, Balant-Gorgia AE, Balant LP: Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Ther Drug Monit 25:46-53, 2003
PubMed
23) Penzak SR, Hon YY, Lawhorn WD et al: Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers. J Clin Psychopharmacol 22:366-370, 2002
PubMed
24) Macias WL, Bergstrom RF, Cerimele BJ et al: Lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men. Pharmacotherapy 18:1237-1248, 1998
PubMed
25) Callaghan JT, Cerimele BJ, Kassahun KJ et al: Olanzapine: interaction study with imipramine. J Clin Pharmacol 37:971-978, 1997
PubMed
26) Ring BJ, Binkley SN, Vandenbranden M et al: In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. Br J Clin Pharmacol 41:181-186, 1996
PubMed
27) Wong YW, Yeh C, Thyrum PT: The effects of concomitant phenytoin administration on the steadystate pharmacokinetics of quetiapine. J Clin Psychopharmacol 21:89-93, 2001
PubMed
28) Fitzgerald BJ, Okos AJ: Elevation of carbamazepine-10, 11-epoxide by quetiapine. Pharmacotherapy 22:1500-1503, 2002
PubMed
29) Strakowski SM, Keck PE Jr, Wong YW et al: The effect of multiple doses of cimetidine on the steady state pharmacokinetics of quetiapine in men with selected psychotic disorders. J Clin Psychopharmacol 22:201-205, 2002
PubMed
30) Potkin SG, Thyrum PT, Alva G et al: Pharmacokinetic Study Group. Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine. J Clin Psychopharmacol 22:174-182, 2002
 
31) Potkin SG, Thyrum PT, Alva G et al: The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine. J Clin Psychopharmacol 22:121-130, 2002
PubMed
32) Furst BA, Champion KM, Pierre JM et al: Possible association of QTc interval prolongation with coadministration of quetiapine and lovastatin. Biol Psychiatry 51:264-265, 2002
PubMed
33) Yasui-Furukori N, Furuya R, Takahata T et al: Determination of a new atypical antipsychotic agent perospirone and its active metabolite by automated column-switching high performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 789:239-245, 2003
 
34) Prakash C, Kamel A, Cui D et al: Identification of the major human liver cytochrome P450 isoform (s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. Br J Clin Pharmacol 49 (Suppl 1):S35-S42, 2000
 
35) Miceli JJ, Smith M, Robarge L et al: The effects of ketoconazole on ziprasidone pharmacokinetics--a placebo-controlled crossover study in healthy volunteers. Br J Clin Pharmacol 49 (Suppl 1):S71-S76, 2000
 
36) Miceli JJ, Anziano RJ, Robarge L et al: The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers. Br J Clin Pharmacol 49 (Suppl 1):S65-S70, 2000
 
37) Apseloff G, Mullet D, Wilner KD et al: The effects of ziprasidone on steady-state lithium levels and renal clearance of lithium. Br J Clin Pharmacol 49 (Suppl 1):S61-S64, 2000
 
38) Wilner KD, Hansen RA, Folger CJ et al: The pharmacokinetics of ziprasidone in healthy volunteers treated with cimetidine or antacid. Br J Clin Pharmacol 49 (Suppl 1):S57-S60, 2000
PubMed
39) Wilner KD, Demattos SB, Anziano RJ et al: Ziprasidone and the activity of cytochrome P450 2D6 in healthy extensive metabolizers. Br J Clin Pharmacol 49 (Suppl 1):S43-S47, 2000
 
40) Muirhead GJ, Harness J, Hoh PR et al: Ziprasidone and the pharmacokinetics of a combined oral contraceptive. Br J Clin Pharmacol 49 (Suppl 1):S49-S56, 2000
 
41) Liu HC, Lin SK, Sung SM: Extrapyramidal side effect due to drug combination of risperidone and donepezil. Psychiatry Clin Neurosci 56:479, 2002
PubMed
P.214 掲載の参考文献
1) 厚生労働省: 平成9年糖尿病実態調査報告書. 1999
 
2) Mukherjee S, Decina P, Bocola V et al: Diabetes mellitus in schizophrenic patients. Compr Psychiatry 37:68-73, 1996
PubMed
3) Mukherjee S, Schnur DB, Reddy R: Family history type 2 diabetes in schizophrenic patients. Lancet 1:495, 1989
PubMed
4) Arnesson GA: Phenothiazine derivatives and glucose metabolism. J Neuropsychiatry 5:181, 1964
 
5) 厚生労働省医薬局安全対策課: 緊急安全性情報: 抗精神病薬ジプレキサ(R)錠 (オランザピン) 投与中の血糖上昇による糖尿病性ケトアシドーシス及び糖尿病性昏睡について. 2002年4月
 
6) 厚生労働省医薬局安全対策課: 緊急安全性情報: 抗精神病剤セロクエル25mg錠, 同100mg錠 (フマル酸クエチアピン) 投与中の血糖値上昇による糖尿病性ケトアシドーシス及び糖尿病性昏睡について. 2002年11月
 
7) 岡田俊: 新規抗精神病薬と耐糖能異常. 臨床精神薬理 5:1405-1412, 2002
 
8) Stahl MH: Essential psychopharmacology: Neuro-scientific basis and practical applications, Second edition. Cambridge University Press, Cambridge, 2000
 
9) Hagg S, Joelsson L, Mjorndal T et al: Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychol 59:294-299, 1998
 
10) Henderson DC, Cagliero E, Gray C et al: Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 157:975-981, 2000
PubMed
11) Goldstein LE, Henderson DC: Atypical antipsychotic agents and diabetes mellitus. Prim Psychiatry 7:65-68, 2000
 
12) Sobel M, Jaggers ED, Franz MA: New-onset diabetes mellitus associated with the initiation of quetiapine treatment. J Clin Psychiatry 60:556-557, 1999
PubMed
13) Procyshyn RM, Pande S, Tse G: New-onset diabetes mellitus associated with quetiapine. Can J Psychiatry 45:668-689, 2000
PubMed
14) Wilson DR, D'Souza L, Sarkar N et al: New-onset diabetes and ketoacidosis with atypical antipsychotics. Schizophr Res 59:1-6, 2003
PubMed
15) Domon SE, cargile CS: Quetiapine-associated hyperglycemia and hypertriglyceridemia. J Am Acad Child Adolesc Psychiatry 41:495-496, 2002
PubMed
16) Croarkin PE, Jacobs KM, Bain BK: Diabetic ketoacidosis associated with risperidone treatment? Psychosomatics 41:369-370, 2000
PubMed
17) Wirshing DA, Pierre JM, Eyeler J et al: Risperidone-associated new-onset diabetes. Biol Psychiatry 50:148-149, 2001
PubMed
18) Mallya A, Chawla P, Boyer SK et al: Resolution of hyperglycemia on risperidone discontinuation: a case report. J Clin Psychiatry 63:453-454, 2002
PubMed
19) Colli A, Cocciolo M, Francobandiera C et al: Diabetic ketoacidosis associated with clozapine treatment. Diabetes Care 22:176-177, 1999
 
20) Fertig MK, Brooks VG, Shelton PS et al: Hyperglycemia associated with olanzapine. J Clin Psychiatry 59:687-689, 1998
PubMed
21) Gatta B, Rigallaeu V. Gin H: Diabetic ketoacidosis with olanzapine treatment. Diabetes Care 22:1002-1003, 1999
 
22) Goldstein LE, Spom J, Brown S et al: New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 40:438-443, 1999
 
23) Kamran A, Doraiswamy PM, Jane JL et al: Severe hyperglycemia associated with high doses of clozapine. Am J Psychiatrs. 151:1395, 1994
 
24) Kostakoglu AE, Yazici KM, Erbas T et al: Ketoacidosis as a side effect of clozapine: a case report. Acta Psychiatr Scand 93:217-218, 1996
PubMed
25) Koval MS, Rames LJ, Christie S: Diabetic ketoacidosis associated with clozapine treatment. Am J Psychiatry 151:1520-1521, 1994
PubMed
26) Lindenmayer J-P, Patel R: Olanzapine-induced ketoacidosis with diabetes mellitus. Am J Psychiatry, 156:1471, 1999
PubMed
27) Luna B, Feinglos MN: Drug-induced hyperglycemia. JAMA 286:1945-1948, 2001
PubMed
28) Thompson J, Chengappa KNR, Good CB et al: Hepatitis, hyperglycemia, pleural effusion, eosinophilia, hematuria and proteinuria occurring earl in clozapine treatment. Int Clinical Psychopharmacol 13:95-98, 1998
 
29) Von Hayek D, Huttl V, Reiss J et al: Hyperglycemia and ketoacidosis on olanzapine. Nervenarzt 70:836-837, 1999
PubMed
30) Koller E, Malozowski S, Doraiswamy PM: Atypical antipsychotic drugs and hyperglycemia in adolescents. JAMA 286:2547-2548, 2001
PubMed
31) Seaburg HL, McLendon BM, Doraiswamy PM: Olanzapine-associated severe hyperglycemia, ketonuria, and acidosis: case reports and review of literature. Pharmacotheraphy 21 :1448-1454, 2001
 
32) Wirshing DA, Spellberg BJ, Erhart SM et al: Novel antipsychotics and new onset diabetes. Biol Psychiatry 44:778-783, 1998
PubMed
33) Mir S, Taylor S: Atypical antipsychotics and hyperglycaemia. Int Clin Psychopharmacol 16:63-74, 2001
 
34) Sernyak MJ, Leslie DL, Alarcon RD et al: Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 159:561-566, 2002
PubMed
35) Gianfrancesco FD, Grogg AL, Mahmoud RA et al: Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry 63:920-930, 2002
PubMed
36) Koro CE, Fedder DO, L'Italien GJ et al: Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 325:243-247, 2002
PubMed
37) Caro JJ, Ward A, Levinton C et al: The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry 63:1135-1139, 2002
PubMed
38) Meyer JM: A retrospective comparison of weight, lipid, and glucose changes between risperidone-and olanzapine-treated inpatients: metabolic outcome after 1 year. J Clin Psychiatry 63:425-433, 2002
 
39) Lindenmayer J-P, Czbor P, Volavka J et al: Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical and atypical antipsychotics. Am J Psychiatry 160:290-296, 2003
 
40) Newcomer JW, Haupt DW, Fucetola R et al: Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 59:337-345, 2002
PubMed
41) Yazici KM, Erbas T, Yazici AH: The effect of clozapine on glucose metabolism. Exp Clin Endocrinol Diabetes 106:475-477, 1998
PubMed
42) Melkersson KI, Hulting A-L, Brismar KE: Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychosis. J Clin Psychiatry 60:783-791, 1999
PubMed
43) Allison DB, Mentore JL, Heo M et al: Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156:1686-1696, 1999
PubMed
44) Melkersson KI, Hulting A-L, Brismar KE: Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 61:742-749, 2000
PubMed
45) Rigalleau V, Gatta B, Bonnaudt S et al: Diabetes as a result of atypical anti-psychotic drug: a report of three cases. Diabet Med 17:484-486, 2000
 
46) Pierides M: Clozapine monotherapy and ketoacidosis. Br J Psychiatry 171 :90-91, 1997
PubMed
47) Dwyer DS, Pinkofski HB, Liu Y et al: Antipsychotic drugs affect glucose uptake and the expression of glucose transpoters in PC12 cells. Prog Neuro-Psychopharmacol & Biol Psychiat 23:69-80, 1999
 
48) Dwyer DS, Bradley RJ, Kablinger AS et al: Glucose metabolism in relation to schizophrenia and antipsychotic drug treatment. Ann Clin Psychiatry 13:103-113, 2001
PubMed
49) Hedenmalm K, Hagg S, Stahl M et al: Glucose intolerance with atypical antipsychotics. Drug Saf 25:1107-1116, 2002
PubMed
50) Henderson DC: Atypical antipsychotic-induced diabetes mellitus: How strong is the evidence? CNS Drugs 16:77-89, 2002
PubMed
51) Reinstein MJ, Sirotovskaya LA, Jones LE et al: Effect of clozapine-quetiapine combination therapy on weight and glycemic control. Clin Drug Invest 18:99-104, 1999
 
52) Liebzeit KA, Markowitz JS, Caley CF: New onset diabetes and atypical antipsychotics. Eur Neuropsychopharmacol 11:25-32, 2001
PubMed
53) Ghaeli P, Dufresne RL: Elevated serum triglycerides with clozapine resolved with risperidone in four patients. Pharmacotheraphy 19:1099-1101, 1999
 
54) Spivak B, Roitman S, Vered Y et al: Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine. Clin Neuropharmacol 21:245-250, 1998
PubMed
55) Sheitman BB, Bird PM, Binz W et al: Olanzapineinduced elevation of plasma triglyceride levels. Am J Psychiatry 156:1471-1472, 1999
PubMed
56) Osser DN, Najarian DM, Dufresne RL: Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry 60:767-770, 1999
 
57) Meyer JM: Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol 21:369-374, 2001
PubMed
58) Wirshing DA, Boyd JA, Meng LR et al: The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 63:856-865, 2002
 

PART 6 将来展望

P.222 掲載の参考文献
1) Buckley PF: Broad therapeutic uses of atypical antipsychotic medications. Biol Psychiatry 50:912-924, 2001
PubMed
2) Segal J, Berk M, Brook S: Risperidone compared with both lithium and haloperidol in mania: adouble-blind randomized controlled trial. Clin Neuropharmacol 21:176-180, 1998
 
3) Sachs GS, Grossman F, Ghaemi SN et al: Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry 159:1146-1154, 2002
PubMed
4) Vieta E, Goikolea JM, Corbella B et al: Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-month, multicenter, open study. J Clin Psychiatry 62:818-825, 2001
PubMed
5) Tohen M, Sanger TM, McElroy SL et al: Olanzapine versus placebo in the treatment of acute mania, Am J Psychiatry 156:702-709, 1999
PubMed
6) Tohen M, Jacobs TG, Grundy SL et al: Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Arch Gen Psychiatry 57:841-849, 2000
 
7) Tbhen M, Baker RW, Altshuler LL et al: Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry 159:1011-1017, 2002a
 
8) Tohen M, Chengappa KN, Suppes T et al: Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 9:62-69, 2002b
 
9) Baker RW, Tohen M, Fawcett J: Acute dysphoric mania: treatment response to olanzapine versus placebo. J Clin Psychopharmacol 23:132-137, 2003
PubMed
10) Gonzalez-Pinto A, Tohen M, Lalaguna B et al: Treatment of bipolar I rapid cycling patients during dysphoric mania with olanzapine. J Clin Psychopharmacol 22:450-454, 2002
PubMed
11) Vieta E, Parramon G, Padrell E et al: Quetiapine in the treatment of rapid cycling bipolar disorder. Bipolar Disord 4:335-340, 2002
PubMed
12) 杉田荘太郎: 塩酸ペロスピロンの使用経験. Progress in Medicine 21:2397-2401, 2001
Medical*Online
13) Ostroff RB, Nelson JC: Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry 60:256-259, 1999
PubMed
14) Rothschild AJ, Bates KS, Boehringer KL et al: olanzapine response in psychotic depression. J Clin Psychiatry 60:116-118, 1999
PubMed
15) Matthews JD, Bottonari KA, Polania LM et al: An open study of olanzapine and fluoxetine for psychotic major depressive disorder: interim analyses. J Clin Psychiatry 63:1164-1170, 2002
PubMed
16) Shelton RC, Tollefson GD, Tohen M et al: A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 158:131-134, 2001
PubMed
17) Zhang W, Peny KW, Wong DT et al: Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 23:250-262, 2000
 
18) Zarate CA Jr, Rothschild A, Fletcher KE et al: Clinical predictors of acute response with quetiapine in psychotic mood disorders. J Clin Psychiatry 61:185-189, 2000
PubMed
19) Mullen J, Jibson MD, Sweitzer D et al: Acomparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin Ther 23:1839-1854, 2001
 
20) Saxena S, Wang D, Bystritsky A et al: Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry 57:303-306, 1996
PubMed
21) Stein DJ, Bouwer C, Hawkridge S et at: Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. J Clin Psychiatry 58:119-122, 1997
 
22) Pfanner C, Marazziti D, Dell'Osso L et al: Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study. Int Clin Psychopharmacol 15:297-301, 2000
PubMed
23) McDougle CJ, Epperson CN, Pelton GH et al: A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 57:794-801, 2000
PubMed
24) Weiss EL, Potenza MN, McDougle CJ et al: Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series. J Clin Psychiatry 60:524-527, 1999
 
25) Koran LM, Ringold AL, Elliott MA: Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 61:514-517, 2000
PubMed
26) Bogetto F, Bellino S, Vaschetto P et al: Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial. Psychiatry Res 96:91-98, 2000
PubMed
27) Stewart RS, Nejtek VA: An open-label, flexible dose study of olanzapine in the treatment of trichotillomania. J Clin Psychiatry 64:49-52, 2003
PubMed
28) Denys D, van Megen H, Westenberg H: Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study. J Clin Psychiatry :63:700-703, 2002
PubMed
29) Atmaca M, Kuloglu M, Tezcan E et al: Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study. Int Clin Psychopharmacol 17:115-119, 2002
PubMed
30) Maina G, Albert U, Ziero S et al: Antipsychotic augmentation for treatment resistant obsessive-compulsive disorder: what if antipsychotic is discontinued? Int Clin Psychopharmacol 18:23-28, 2003
PubMed
31) Rocca P, Marchiaro L, Cocuzza E et al: Treatment of borderline personality disorder with risperidone. J Clin Psychiatry 63:241-244, 2002
PubMed
32) Zanarini MC, Frankenburg FR: Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry 62:849-854, 2001
PubMed
33) 神出誠一郎, 石田展弥, 山田尚登ほか: Risperdoneが奏効した分裂病型人格障害の1症例. 臨床精神薬理1:637-640, 1998
 
34) 山根秀夫, 大川匡子: Perospirone が著効した分裂病型人格障害の1例. 精神医学44:447-449, 2002
 
35) McDougle CJ, Holmes JP, Carlson DC et al: A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry 55:633-641, 1998
PubMed
36) McCracken JT, McGough J, Shah B et al: Risperidone in children with autism and serious behavioral problems. N Engl J Med 347:314-321, 2002
PubMed
37) Bruggeman R, van der Linden C, Buitelaar JK et al: Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study. J Clin Psychiatry 62:50-56, 2001
 
38) Dion Y, Annable L, Sandor P et al: Risperidone in the treatment of tourette syndrome: a double-blind, placebo-controlled trial. J Clin Psychopharmacol 22:31-39, 2002
 
39) Budman CL, Gayer A, Lesser M et al: An open label study of the treatment efficacy of olanzapine for Tourette's disorder. J Clin Psychiatry 62:290-294, 2001
PubMed
P.233 掲載の参考文献
1) Sharma T: Cognitive effects of conventional and atypical antipsychotics in schizophrenia. Br J Psychiatry 174:44-51, 1999
 
2) Breier A: Cognitive deficit in schizophrenia and its neurochemical basis. Br J Psychiatry 37 (Suppl):16-18, 1999
 
3) Lee MA, Thompson PA, Meltzer HY: Effects of clozapine on cognitive function in schizophrenia. J Clin Psychiatry 55 (Suppl B):82-87, 1994
 
4) Harvey PD, Keefe RSE: Studies of cognitive change in patient with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 158:176-184, 2001
 
5) Davidson M: Risperidon. Evidence from experience Risperidon; 経験から得たエビデンス. 臨精薬理 3:ll91-1202, 2000
 
6) Weinberger DR, Gallhofer B: cognitive functions in schizophrenia. Int Clin Psychopharmacol 4:29-36, 1997
 
7) Tecce JJ, Cole TO.: Psychophysiologic responses of schizophrenics to drugs. Psychopharmacologia 24:159-200, 1997
 
8) Goldberg TE, Weinberger DR: effects of neuroleptic medication on the cognition of patients with schizophrenia: A review recent studies. J Clin Psychiatry 57 (Suppl 9) 62-65, 1996
 
9) World Health Organization: The Tenth Revision of the International Classification of Diseases and Related Health Problems. Geneva, 1992
 
10) 国民体力づくり事業協会: 壮年体力テストの方法と運営. 竹井機器土業機式会社, 1970
 
11) Cassens G, Inglis AK, Appelbaum PS et al: Neuroleptics: Effects on neuropsychological function in chronic schizophrenic patients. Schizophrenia Bull 16:477-479, 1990
PubMed
12) King DJ: The effect of neuroleptics on cognitive and psychomotor function. Br J Psychiatry 157:799-811, 1990
PubMed
13) Classen W, Laux G: Sensorimotor and cognitive performance of schizophrenic in patients treated with haloperidol, flupenthixol or clozapine. Pharmacopsychiatry 21:295-297, 1988
PubMed
14) Goldberg TE, Greenberg RD, Griffin SJ et al: The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry 162:43-48, 1993
PubMed
15) David LB: Information processing and Attention Dysfunction in schizophrenia. Schizophrenia Bull 19:233-259, 1993
 
16) Yerkes RM, Dodson JD: The relation of strength of stimulus to rapidity of habit-formation. J Comp Neurol Psychol 18:459-482, 1976
 
17) Landers DM: The arousal-performance relationship. Research guarterly for Exercise and Sport 4:262-278, 1980
 
18) MaGrath J: The pathogenesis of thought disorder in Schizophrenia. In: A neuropsychological perspective. ed by. Pantelis C, Nelson HE, Barnes TRE John Wiley and Sons, 1996, pp. 183-204
 
19) Cheu EYH, Mckeuna PJ: Memory dysfunction in schizophrenia. In: A neuropsychological perspective. ed by. Pantelis C, Nelson HE, Barnes TRE John Wiley and sons, New York, 1996, pp. 107-124
 
20) Baddely AD: Working memory. Oxford University Press, Oxford, 1986
 
21) Buchanan RW, Strauss ME, Breier A et al: Attentional Impairments in Deficit and Nondeficit Form of Schizophrenia. Am J Psychiatry 54:363-370, 1997
 
22) Nuechterlin KH, Edell WS, Noris M et al: Attentional vulnerability icatars, thought disorder and negative symptoms. Schizophrenia Bull 12:408-426, 1986
 
23) Pandurangi AK, Sax KW, Pelonero AL et al: Sustained attention and positive formal thought disorder in schizophrenia. Schizophrenia Research 13:109-116, 1994
PubMed
24) 猪飼道夫: 生理学から見た体力と技術. 体育の科学 18:291-294, 1968
 
25) 猪飼道夫: 調整力-その生理学的考察. 体力の科学 22:5-10, 1972
 
26) Fitts PM: The information capacity of the human motor system in controlling the amplitude of movement. Journal of Experimental Psychology 47:381-391, 1954
PubMed
27) Penn DL, Mueser KT, Spaulding W et al: Information processing and social competence in chronic schizophrenia. Schizophrenia Bull 212:269-281, 1995
 
28) Schwarts BD, Winstead DK: Visible persistence in acute and chronic schizophrenics. Biol Psychiatry 17:1377-1387, 1982
 
29) Zubin J, Spring B: Vulunerability-A new view of schizophrenia. Journal of Abnormal Psychology 86:103-123, 1977
PubMed
30) 丹羽真一, 小林恒司, 廣山祐治: 分裂病の認知障害, 陰性症状, 生活障害. 精神科レビュー27「精神疾患の認知障害 (丹羽真一編), ライフサイエンス, 東京. 1988, pp58
 
31) 皿田洋子: 精神分裂病を対象とした生活技能訓練とその効果. 精神神経学雑誌 94:171-188, 1992
 
32) American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4thed (DSM-IV). American Psychiatric Press, Washington DC, 1994
 
33) 岩崎晋也, 宮内勝, 大島巌ほか:精神障害者社会生活評価尺度の開発とその意義. 季刊精神科診断学 5:221-231, 1994
 
34) 田崎美弥子, 中根允文: WHOQOL短縮版とその手引き. 金子書房, 1997
 
35) 佐々木信幸: 急性期治療後の社会復帰にいたる過程-「目覚め」と「いそぎ」を中心に-, 臨床精神薬理 5:1037-1043, 2002
 
36) Liberman RP編 (安西信雄, 池淵恵美監訳): 自立生活技能 (SILS) プログラム. 丸善. 1995
 
37) 猪飼道夫: 運動生理学入門. 杏林, 東京, 1963, pp. 81
 
P.241 掲載の参考文献
1) 社会保障審議会障害者部会精神障害者分会の報告書および厚生労働省の資料の概要は厚生労働省ホームページ (http://www.mhlw.go.jp/shingi/2002/12/s1219-7.htmlおよびhttp://www.mhlw.go.jp/shingi/2002/01/s0128-7al.html) で閲覧可能
 
2) 藤井康男: 新しい抗精神病薬によって精神分裂病治療成果を向上させるには? 臨床精神医学 30:1039-1045, 2001
Medical*Online
3) 佐々木信幸, 山田信吾, 中野倫仁ほか: リスペリドンによる「いそぎ」症状-4症例の検討から. 第97回日本精神神経学会総会, 大阪, 2001
 
4) 諸川由美代: 非定型抗精神病薬-SDA-の社会復帰に果たす役割. 臨床精神薬理 4:317-324, 2001
 
5) 浅井邦彦: 精神分裂病のリハビリテーション. Schizophrenia Practice 2:1-15, 2001
 
6) 安西信雄, 佐藤新, 灘谷聡昭ほか: 精神科リハビリテーションに果たす新薬の有用性. 精神科治療学, 16:1289-1296, 2001
 
7) 浅井邦彦: 病院治療地域精神医療との関連. 臨床精神医学講座20「精神科リハビリテーション・地域精神医療」, 中山書店, 東京, 1999, pp. 99-114
 
P.246 掲載の参考文献
1) Knapp M: Pharmacoeconomic evaluation and psychiatry. In: Pharmacoeconomics in Psychiatry (ed. by Taylor D, Knapp M, Kerwin R), Martin Dunitz, London, 2002, pp. 1-14
 
2) Knapp M: The economic perspective: Framework and principles. In: The Economic Evaluation of Mental Health Care, ed. by Knapp M, Arena, Aldershot, 1995, pp. 1-26
 
3) 山内慶太: 薬物療法の経済評価の基本的な考え方と留意点-精神医療の特質に即して-. 臨床精神薬理 6:837-843, 2003
 
4) Hamann J, Leucht S, Kissling W: Are the second-generation antipsychotics cos-effective?: A critical review on the background of different health systems. Pharmacopsychiatry 36:18-26, 2003
 
5) Albright PS, Livingstone S, Keegan DL: Reduction of health care resouce utilisation and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy :a retrospective analysis using the Saskatchewan Health Linkable Databases. Clin Drug Invest 11 : 289-299, 1996
 
6) Moore DB, Kelly DL, Sherr JD et al: Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone. Am J Health Syst Pharm 55 (Suppl 4):S17-19, 1998
 
7) Sacristan JA, Gomez JC, Martin C et al: Pharmacoeconomic assessment of olanzapine in the treatment of refractory schizophrenia based on a pilot clinical study. Clinical Drug Investigation 15:29-35, 1998
 
8) Hamilton SH, Revicki DA, Edgell ET et al: Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial Pharmacoeconomics 15:469-480, 1999
PubMed
9) Le Pen C, Lilliu H, Allicar MP et al: Comparaison economique de rolanzapine versus haloperidol dans le traitement de le schizophrenie en France. Encephale 25:281-286, 1999
 
10) Lynch J, Morrison J, Graves N et al: The health economic implications of treatment with quetiapine: an audit of long-term treatment for patients with chronic schizophrenia. Eur Psychiatry 16:307-312, 2001
PubMed
11) Edgell ET, Andersen SW, Johnstone BM et al: Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia. Pharmacoeconomics 18:567-579, 2000
PubMed
12) Lewis M, McCrone P, Frangou S: Service use and costs of treating schizophrenia with atypical antipsychotics. J Clin Psychiatry 62:749-756, 2001
PubMed
13) 湯尾高根, 山内慶太: 医療経済学から見た新規抗うつ薬. 臨床精神薬理 5:715-723, 2002
 
14) 山内慶太: 薬物療法とその他の治療法の併用の意義-服薬コンプライアンスの向上と再発予防-. 臨床精神薬理 2:1061-1067, 1999
 
15) Davies LM, Drummond MF: Economics and Schizophrenia: The real cost. Br J Psychiatry 165 (Suppl 25):18-21, 1994
 
16) Weiden PJ, Olfson M: Cost of relapse of schizophrenia. Schizophrenia Bulletin 21:419 429, 1995
 
17) 山内慶太: 精神医療における新しい支払い方式に関する基礎的研究-ケースミックス分類の開発-. 病院管理 34:155-167, 1997
 
P.254 掲載の参考文献
1) 中込和幸: 新しい薬は認知機能に影響するか. 精神科治療学 16:1119-1129, 2001
 
2) Meltzer HY, McGurk SR: The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25:233-255, 1999
PubMed
3) Velligan DI, Newcomer J, Pultz J et al: Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophr Res 53:239-248, 2002
PubMed
4) Bilder RM, Goldman RS, Volavka J et al: Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 159:1018-1028, 2002
 
5) Harvey PD, Green MF, McGurk SR et al: Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. Psychopharmacology, in print (epub ahead of print)
 
6) Harvey PD, Keefe RSE: Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 158:176-184, 2001
 
7) Purdon SE, Jones BDW, Stip E et al: Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch Gen Psychiatry 57:249-258, 2000
PubMed
8) Meltzer HY, Park S, Kessler R: Cognition, schizophrenia, and the atypical antipsychotic drugs. Proc Nat Acad Sci USA 96:13591-13593, 1999
PubMed
9) Green MF: What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153:321-330, 1996
PubMed
10) Green MF, Kern RS, Braff DL et at: Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the "right stuff?" Schizophr Bull 26:119-136, 2000
 

PART 7 基礎編

P.262 掲載の参考文献
1) Prasad S, Semwal P, Deshpande S et al: Molecular genetics of schizophrenia: past, present and future. J Biosci 27 (Suppl 1):35-52, 2002
 
2) Masellis M, Basile VS, Ozdemir V et al: Pharmacogenetics of antipsychotic treatment: lessons learned from clozapme. Biol Psychiatry 47:252-266, 2000
PubMed
3) Veenstra-Vander Weele J, Anderson GM, Cook EH Jr: Pharmacogenetics and the serotonin system: initial studies and future directions. Eur J Pharmacol 410:165-181, 2000
PubMed
4) Basile VS, Masellis M, Potkin SG et al: pharmacogenomics in schizophrenia: the quest for individualized therapy. Hum Mol Genet 11:2517-2530, 2002
PubMed
5) Egan MF, Kojima M, Callicott JH et al: The BDNF va166 met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112:257-269, 2003
PubMed
P.268 掲載の参考文献
1) Basile VS, Masellis M, Potkin SG et al: Pharmacogenomics in schizophrenia: the quest for individualized therapy. Hum Mol Genet 11:2517-2530, 2002
PubMed
2) Abi-Dargham A, Rodenhiser J, Printz D et al: From the cover: increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 97:8104-8109, 2000
 
3) Klein C, Brin MF Kramer P et al: Association of a missense change in the D2 dopamine receptor with myoclonus dystonia. Proc Natl Acad Sci USA 96:5173-5176, 1999
PubMed
4) Klein C, Gurvich N, Sena-Esteves M et al: Evaluation of the role of the D2 dopamine receptor in myoclonus dystonia. Ann Neurol 47:369-373, 2000
PubMed
5) Itokawa M, Arinami T, Futamura N et al: A structural polymorphism of human dopamine D2 receptor, D2 (Ser311-->Cys). Biochem Biophys Res Commun 196:1369-1375, 1993
PubMed
6) Arinami T, Gao M, Hamaguchi H et al: A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum Mol Genet 6:577-582, 1997
PubMed
7) Virgos C, Martorell L, Valero J et al: Association study of schizophrenia with polymorphisms at six candidate genes. Schizophr Res 49:65-71, 2001
PubMed
8) Dubertret C, Gorwood P, Gouya L et al: Association and excess of transmission of a DRD2 haplotype in a sample of French schizophrenic patients. Schizophr Res 49:203-212, 2001
 
9) Cravchik A, Sibley DR, Gejman PV: Functional analysis of the human D2 dopamine receptor missense variants. J Biol Chem 271 :26013-26017, 1996
PubMed
10) Jonsson EG, Nothen MM, Grunhage F et al: Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry 4:290-296, 1999
PubMed
11) Noble EP: D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes. Am J Med Genet 116B:103-125, 2003
PubMed
12) Duan J, Wainwright MS, Comeron JM et al: Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet 12:205-216, 2003
PubMed
13) Arinami T, Itokawa M, Enguchi H et al: Association of dopamine D2 receptor molecular variant with schizophrenia. Lancet 343:703-704, 1994
PubMed
14) Jonsson EG, Sillen A, Vares M et al: Dopamine D2 receptor gene Ser311Cys variant and schizophrenia: association study and meta-analysis. Am J Med Genet 119B:28-34, 2003
PubMed
15) Suzuki A, Mihara K, Kondo T et al: The relationship between dopamine D2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients. Pharmacogenetics 10:335-341, 2000
PubMed
16) Mihara K, Suzuki A, Kondo T et al: Relationship between Taq1 A dopamine D2 receptor (DRD2) polymorphism and prolactin response to bromperidol. Am J Med Genet 105:271-274, 2001
PubMed
17) Mihara K, Kondo T, Suzuki A et al: Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome. Am J Med Genet 117B:57-60, 2003
PubMed
18) Kaiser R, Tremblay PB, Klufmoller F et al: Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia. Mol Psychiatry 7:695-705, 2002
PubMed
19) Harrison PJ: Neurochemical alterations in schizophrenia affecting the putative receptor targets of atypical antipsychotics. Focus on dopamine (D1, D3, D4) and 5-HT2A receptors. Br J Psychiatry 38:12-22,1999
 
20) Lundstrom K, Turpin MP: Proposed schizophreniarelated gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system. Biochem Biophys Res Commun 225:1068-1072, 1996
PubMed
21) Jonsson EG, Flyckt L, Burgert E et al: Dopamine D3 receptor gene Ser9Gly variant and schizophrenia: association study and meta-analysis. Psychiatr Genet 13:1-12, 2003
PubMed
22) Lerer B, Segman RH, Fangerau H et al: Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 27:105-119, 2002
PubMed
23) Okuyama Y, Ishiguro H, Tbru M et al: A genetic polymorphism in the promoter region of DRD4 associated with expression and schizophrenia. Biochem Biophys Res Commun 258:292-295, 1999
 
24) Jonsson EG, Sedvall GC, Nothen MM et al: Dopamine D4 receptor gene (DRD4) variants and schizophrenia: meta-analyses. Schizophr Res 61:111-119, 2003
PubMed
25) Cohen BM, Ennulat DJ, Centorrino F et al: Polymorphisms of the dopamine D4 receptor and response to antipsychotic drugs. Psychopharmacology (Berl) 141:6-10, 1999
PubMed
P.275 掲載の参考文献
1) Kaczmarek L: c-Fos in learning: beyond the mapping of neuronal activity, In: Handbook of chemical neuroanatomy Volume 19, ed by Kaczmarek L, Robertson HA, Elsevier Science, Amsterdam, 2002, pp. 189-215
 
2) Fink-Jensen A: Novel pharmacological approaches to the treatment of schizophrenia. Dan Med Bull 47:151-167, 2000
 
3) Ananth J, Burgoyne KS, Gadasalli R et al: How do the atypical antipsychotics work? J Psychiatry Neurosci 26:385-394, 2001
 
4) Hope BT: Cocaine and the AP-1 transcription factor complex. Ann NY Acad Sci 30:1-6, 1998
 
5) Sharp FR, Liu J, Nickolenko J et al: NMDA and D1 receptors mediate induction of c-fos and junB genes in striatum following morphine administration: implications for studies of memory. Behav Brain Res 66:225-230, 1995
PubMed
6) 西川徹, 海野麻未, 佐藤大輔ほか: 分裂病症状の動物における新しいin vivo評価法の探索. 日本薬理学雑誌108 (補冊1):53-58, 1996
 
7) Robertson GS, Fibiger HC: Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 46:315-328, 1992
PubMed
P.280 掲載の参考文献
1) Gottesman II: Schizophrenia Genesis: The Origins of Madness. W. H. Freeman and Company, New York, 1991 (内沼幸雄, 南光進一郎監訳: 分裂病の起源, 日本評論社, 東京, 1992)
 
2) 南光進一郎:統合失調症の分子病態解析. 遺伝医学別冊「これだけは知っておきたい遺伝子医学の基礎研究」:260-264, 2003
 
3) 赤羽晃寿, 南光進一郎: 精神疾患の遺伝子研究: 候補遺伝子の解析と関連研究の技法. こころの臨床アラカルト21:463-468, 2002
 
4) 中野祐子, 赤羽晃寿, 南光進一郎: 統合失調症遺伝子の関連解析の現状. Schizophrenia Frontier 4:8-11, 2003
 
5) Harrison PJ, Owen MJ: Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet 361:417-419, 2003
PubMed
P.288 掲載の参考文献
1) Shenton ME, Dickey CC, Frumin M et al : A review of MRI findings in schizophrenia. Schizoophr Res 49:1-52, 2001
PubMed
2) Wong DF, Wagner HN Jr, Tune LE et al: Posititron emission tomography reveals elevated D2 dopanmine receptors in drug-naive schizophrenics. Science 1119:1558-1563, 1986
 
3) Farde L, Wiesel FA, Stone-Elander S et al: D2 dopamine receptors in neuroleptic-naive schhizophrenic patients. A positron emission tomograaphy study with [11C]raclopride. Arch Gen Psychiatry 47:213-219, 1990
 
4) Suhara T, Sudo Y, Okauchi T et al: Extra stririatal dopamine D2 receptor density and affinity in the human brain measured by 3D PET. Int J Neurophharmacology 2:73-82, 1999
 
5) Suhara T, Okubo Y, Yasuno F et al: Decreaased dopamine D2 receptor binding in the anterior cinngulate cortex in schizophrenia. Arch Gen Psychiatry 59:25-30, 2002
PubMed
6) Benes FM, McSparren J, Bird ED et al: Deficits in small intemeurons in prefrontal and cingulated cortex in schizophrenic and schizoaffective patients. Arch Gen Psychiatry 48:996-1001, 1991
 
7) 0kubo Y, Suhara T, Suzuki K et al: Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 385:634-636, 1997
 
8) Abi-Dargham A, Mawlawi O, Lombardo I et al: Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci 22:3708-3719, 2002
PubMed
9) Karlsson P, Farde L, Halldin C et al: PET study of D1 dopamine receptor binding in neuroleptic-naive patients with schizophrenia. Am J Psychiatry 159:761-767, 2002
PubMed
10) Elkashef AM, Doudet D, Bryant T et al: 6-[18F]-DOPA PET study in patients with schizophrenia. Positron emission tomography. Psychiatry Res 100:1-11, 2000
PubMed
11) Lindstrom LH, Gefvert O, Hagberg G et al: Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11c) DOPA and PET. Biol Psychiatry 46:681-688, 1999
PubMed
12) Laakso A, Vilkman H, Alakare B et al: Striatal dopamine transporter binding in neuroleptic-naive patients with schizophrenia studied with positron emission tomography. Am J Psychiatry 157:269-271, 2000
PubMed
13) Laakso A, Bergman J, Haaparanta M et al: Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia. Schizophr Res 52:115-120, 2001
PubMed
14) Breier A, Su TP, Saunders R et al: Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 94:2569-2574, 1997
PubMed
15) Sun W, Ginovart N, Ko F et al: In vivo evidence for dopamine-mediated internalization of D2-receptors after amphetamine: differential findings with [3H]raclopride versus [3H]spiperone. Mol Pharmacol 63:456-462, 2003
PubMed
16) Hashimoto T, Kitamura N, Kajimoto Y et al: Differential changes in serotonin 5-HT1A and 5-HT2 receptor binding in patients with chronic schizophrenia. Psychopharmacology (Berl) 12 (Suppl 1):S35-39, 1993
 
17) Burnet PW, Eastwood SL, Harrison PJ:5-HT1A and 5-HT2 receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology 15:442-455, 1996
 
18) Tauscher J, Kapur S, Verhoeff NP et al: Brain serotonin 5-HT1A receptor binding in schizophrenia measured by positron emission tomography and [11C] WAY-100635. Arch Gen Psychiatry 59:514-520, 2002
 
19) 0kubo Y, Suhara T, Suzuki K et al: Serotonin 5-HT2 receptors in schizophrenic patients studied by positron emission tomography. Life Sci 66:2455-2464, 2000
 
20) Trichard C, Paillere-Martinot ML, Attar-Levy D et al: No serotonin 5-HT2A receptor density abnormality in the cortex of schizophrenic patients studied with PET. Schizophr Res 31:13-17, 1998
PubMed
21) Lewis R, Kapur S, Jones C et al: Serotonin 5-HT2 receptors in schizophrenia: a PET study using [18F] setoperone in neuroleptic-naive patients and normal subjects. Am J Psychiatry 156:72-78, 1999
PubMed
22) Hanada S, Mita T, Nishino N et al: [3H]muscimol binding sites increased in autopsied brains of chronic schizophrenics. Life Sci 40:259-266, 1987
PubMed
23) Kiuchi Y, Kobayashi T, Takeuchi J et al: Benzodiazepine receptors increase in post-mortem brain of chronic schizophrenics. Eur Arch Psychiatry Neurol Sci 239:71-78, 1989
PubMed
24) Squires RF, Lajtha A, Saederup E et al: Reduced [3H]flunitrazepam binding in cingulate cortex and hippocampus of postmortem schizophrenic brains: is selective loss of glutamatergic neurons associated with major psychoses? Neurochem Res 18:219-223, 1993
PubMed
25) Pandey GN, Conley RR, Pandey SC et al: Benzodiazepine receptors in the post-mortem brain of suicide victims and schizophrenic subjects. Psychiatry Res 71:137-149, 1997
PubMed
26) Abi-Dargham A, Laruelle M, Krystal J et al: No evidence of altered in vivo benzodiazepine receptor binding in schizophrenia. Neuropsychopharmacology 20:650-661, 1999
PubMed
27) Verhoeff NP, Soares JC, D'Souza CD et al: [123I] Iomazenil SPECT benzodiazepine receptor imaging in schizophrenia. Psychiatry Res 91:163-173, 1999
PubMed
28) Busatto GF, Pilowsky LS, Costa DC et al: Correlation between reduced in vivo benzodiazepine receptor binding and severity of psychotic symptoms in schizophrenia. Am J Psychiatry 154:56-63, 1997
PubMed
29) Maeda J, Suhara T, Kawabe K et al: Visualization of alpha5 subunit of GABAA/benzodiazepine receptor by [11C]Ro15-4513 using positron emission tomography. Synapse 47:200-208, 2003
PubMed
30) Haradahira T, Okauchi T, Maeda J et al: A positron-emitter labeled glycine (B) site antagonist, [11C] L-703, 717, preferentially binds to a cerebellar NMDA receptor subtype consisting of Glur epsilon3 subunit in vivo, but not in vitro. Synapse 43:131-133, 2002
 
31) Farde L, Wiesel FA, Halldin C et al: Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45:71-76, 1988
PubMed
32) Kapur S, Zipursky R, Jones C e: al: A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 57:553-559, 2000
 
33) Kapur S. Zipursky RB, Remington G et al: 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 155:921-928, 1998
PubMed
34) Kapur S: A new framework for investigating antipsychotic action in humans: lessons from PET imaging. Mol Psychiatry 3:135-140, 1998
PubMed
35) Pilowsky LS, Mulligan RS, Acton PDet al: Limbic selectivity of clozapine. Lancet 350:490-491, 1997
 
36) Talvik M, Nordstrom AL, Nyberg S et al: No support for regional selectivity in clozapine treated patients: a PET study with [11C]raclopride and [11C] FLB 457. Am J Psychiatry 158:926-930, 2001
PubMed
37) Farde L, Suhara T, Nyberg S et al: A PET-study of [11C] FLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug treated patients. Psychopharmacology (Berl) 133:396-404, 1997
PubMed
38) Yasuno F, Suhara T, Okubo Y et al: Dose relationship of limbic-cortical D2-dopamine receptor occupancy with risperidone. Psychopharmacology (Berl) 154:112-114, 2001
PubMed
39) Suhara T, Okauchi T, Sudo Y et al: Clozapine can induce high dopamine D2 receptor occupancy in vivo. Psychopharmacology (Berl) 160:107-112, 2002
PubMed
40) Tauscher J, Jones C, Remington G et al: Significant dissociation of brain and plasma kinetics with antipsychotics. Mol Psychiatry 17:317-321, 2002
 
41) Takano A, Suhara T, Ikoma Y et al: Estimation of time course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics. Int J Neuropsychopharmacol. In press.
 
42) Farde L, Nordstrom AL, Wiesel FA et al: Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538-544, 1992
PubMed
43) Chou YH, Halldin C, Farde L: Occupancy of 5-HT1A receptors by clozapine in the primate brain: a PET study. Psychopharmacology (Berl) 166:234-240, 2003
 
44) Yokoi F, Grunder G, Biziere K et al: Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmachology 27:248-259, 2002
PubMed

書評

最近チェックした商品履歴

Loading...